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Summary  
Doxorubicin (Adriamycin, DOX) is a widely used anticancer drug which has a well 
demonstrated clinical efficacy. However, it also causes damage to the heart which limits its 
clinical use. The main mechanism of doxorubicin-induced cardiotoxicity involves oxidative 
stress of cardiac cells. Recently, nitric oxide (NO) pathway has been suggested to play a 
significant role in doxorubicin-induced cardiotoxicity.  
Certain natural products, including traditional Chinese herbal medicines, have been 
demonstrated with protective actions on doxorubicin-induced cardiotoxicity. However, the 
scope of their actions and related mechanisms are generally not clear. The aims of this project 
are: 1) to conduct a literature review of actions of natural products on doxorubicin-induced 
cardiotoxicity, and 2) to investigate the effects of tanshinone IIa (TIIa), the active compound of 
Salvia miltiorrhiza, and its synthetic derivatives on doxorubicin-induced cardiotoxicity in 
H9C2 cells, and their relationships to endogenous NO pathways. 
Method: For the literature review, extensive literature search was conducted and relevant 
research publications were identified. For experimental studies, H9C2 cells were cultured 
under standard cell culture operation procedure. Cardiac cell toxicity was assessed by cell 
viability assay. NO production was determined by DAF-2 DA and nitrite assays.  
Results: The actions of various natural compounds/products published previously on 
doxorubicin-induced cardiotoxicity have been reviewed, including their relevant mechanisms 
and relationships to anticancer actions of doxorubicin. Experiments studies found that 
doxorubicin caused a concentration and time dependent cell death in H9C2 cells, which was 
significantly inhibited by the cell permeable superoxide dismutase (SOD) mimetic and 
peroxynitrite scavenger MnTBAP and the inducible NO synthase (iNOS) inhibitors L-NIL. 
NO production in the cell media was also increased by doxorubicin which was inhibited by L-
NIL. Tanshinone IIa at concentrations did not affect the cell viability significantly inhibited 
doxorubicin-induced cell death. It also inhibited doxorubicin-induced increase in NO 
 X 
production. Among 8 synthetic derivatives tested, AFC1 was shown with a protective effect 
on doxorubicin-induced cardiotoxicity at relative low concentrations (0.3µM-10µM). Similar 
effects were observed for AFC2.  
In conclusion, a number of natural products have been shown with protective actions 
against doxorubicin-induced cardiotoxicity, and some exhibit a potential therapeutic value for 
clinical applications. In addition, tanshinone IIa and related synthetic compounds has been 
demonstrated for the first time that its protective actions are associated with endogenous NO 
pathways. Further studies on these compounds may lead to identify new effective therapies to 
reduce or prevent doxorubicin-induced cardiotoxicity.  
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1.1. Doxorubicin  
Doxorubicin (Adriamycin, DOX) is a widely used therapeutic drug for chemotherapy. It 
was discovered initially from Streptomyces peucetius (Arcamone et al., 1967; Bonadonna et 
al., 1969). Doxorubicin belongs to the anthracycline family which has a number of similar 
derivatives, including epirubicin, daunorubicin, and idarubicin (Figure 1). The synthetic 
doxorubicin was obtained in 1969 (Di Marco et al., 1969) which was shown to be more potent 
than daunorubicin (Bonadonna et al., 1970).  
 
Figure 1. Structures of doxorubicin and related compounds. 
 
In early studies, doxorubicin was used to treat leukemia (Monfardini et al., 1969), 
lymphoma (Bonadonna et al., 1969), and the malignancies of the lung (Bonadonna et al., 
1971), breast (Edwards et al., 2011), bladder (Nevin et al., 1974), gastric organs (Yoshikawa 
and Kitaoka, 1971). Now, doxorubicin is commonly used as the second-line drug for both 
topotecan sensitive and resistance ovarian cancers (Gaitanis and Staal, 2010), AIDS-related 
Kaposi’s sarcoma (Sekiya and Imamura, 2008), multiple Myeloma (Gozzetti et al.), and so on 
(Table 1). Doxorubicin is often used in a liposomal preparation as this alters the 
pharmacokinetic properties of doxorubicin, prolonging its circulation time and enhancing its 
localisation to tumours (Sharpe et al., 2002). The total lifetime dose of doxorubicin has been 
suggested to be limited to 550mg/m2 to prevent chronic irreversible cardiotoxicity (Gaitanis 
and Staal, 2010). The overall response rates of patients with ovarian cancer (refractory to 
platinum- and paclitaxel-based chemotherapy) treated by polyethylene glycol liposomal 
doxorubicin (PLD) monotherapy is 46 to 77%, compared to that without doxorubicin 
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treatment 18.3 to 27.6% (Sharpe et al., 2002). A recent systematic review, involving 10 
studies and 608 patients with platinum-sensitive recurrent ovarian cancer using polyethylene 
glycol liposomal doxorubicin in combination with carboplatin (PLD-Carbo) or gemcitabine-
carboplatin (Gem-Carbo), indicates that 60.2% response rate in patients receiving PLD-Carbo, 
(complete, 27.0%; partial, 33.2%), versus 51.4% of patients treated with Gem-Carbo 
(complete, 19.2%; partial, 32.2%) (Holloway et al., 2010). For the metastatic breast cancer, 
doxorubicin has similar affect as vinorelbine and mitomycin C (Sharpe et al., 2002). 
Studies have shown that combination liposomal doxorubicin with highly active 
antiretroviral therapy can reduce myelosuppression and digestive symptoms on AIDS-related 
Kaposi's sarcoma tumours (Sekiya and Imamura, 2008). Moreover, clinical trials showed an 
increased efficacy of doxorubicin when it combined with two chemotherapic agents (Gaitanis 
and Staal, 2010; Sharpe et al., 2002).  
For multiple myeloma treatment, combination of vincristine, dexamethasone and 
doxorubicin (VAD) or liposomal doxorubicin (DVd) are commonly used before autologous 
stem cell transplantation was introduced. An objective response in conventional VAD 
treatment and DVd treatment was 61.4 and 61.3% respectively. Mild or moderate of 
hematological and non-hematological toxicities were observed with alopecia was more 
common after VAD treatment and palmar-plantar erythrodysesthesia more common after 
DVd treatment (Moreau, 2009).  
Studies have demonstrated that doxorubicin-containing chemotherapy showed a good 
response in Hodgkin's lymphoma (Mounier and Ferme, 2010) and non-Hodgkin's lymphoma 
in early stages (Koukourakis and Kouloulias, 2010).  
The side effects of doxorubicin or liposomal doxorubicin include mucositis 
myelosuppression, palmar-plantar erythrodysesthesia, nausea and cardiac toxicity, which can 
be partly managed by delaying or reducing dosages (Gaitanis and Staal, 2010; Sharpe et al., 
2002). 
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Table 1. Clinical use of doxorubicin.  
Indication Treatment Protocol Total 
Dosage 
Main Reference 
Ovarian Cancers Combination: carboplatin 25-40mg/m2  (Garcia et al., 2005; Sharpe et al., 2002)  
AIDS-related Kaposi's 
Sarcoma 
Combination: bleomycin and 
vincristine 
20-50mg/m2 (Gabizon et al., 2003; Sekiya and Imamura, 2008)  
Multiple Myeloma Combination: VAD or DVd* 30mg/m2 (Blade et al., 2011; Moreau, 2009)  
Hodgkin's lymphoma Combination: ABVD* 10-15mg/m2 (Bartlett et al., 2007; Koukourakis and Kouloulias, 2010)  
Non-Hodgkin's lymphoma Combination: MACOP-B or 
VCAP* 
40-80mg/m2 (Macpherson et al., 2006; Mounier and Ferme, 2010; Tulpule et 
al., 2006)  
Metastatic breast cancer Combination vinorelbine 30mg/m2 (Livi et al., 2011) 
 
* VAD: vincristine, dexamethasone and doxorubicin, vincristine, DVd: dexamethasone and liposomal doxorubicin, ABVD: doxorubicin, bleomycin, 
vinblastine, dacarbazine, MACOP-B: methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone; VCAP: vindesine, 
doxorubicin, cyclophosphamide and prednisone.  
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1.2. Mechanism of anti-cancer actions of doxorubicin  
The main mechanism of anti-cancer action of doxorubicin is through interacting with 
tumour cell DNA and affecting cellular apoptosis pathways (Figure 2) (Granados-Principal et 
al., 2010).  
 
Figure 2. Molecular mechanisms of doxorubicin. The main events are: (1) DNA damage, (2) 
production of free radicals and (3) other mechanisms. Adopted from(Granados-Principal et al., 
2010) 
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1.2.1. Targeting tumours DNA synthesis and apoptosis 
There is strong evidence that doxorubicin can directly react with DNA resulting changes 
of DNA topology (Frederick et al., 1990). Doxorubicin combines to the 20S proteasomal 
subunit to form a complex which is decomposed in the nucleus, where doxorubicin reacts 
with topoisomerase II (TOP2) and DNA via DNA-doxorubicin-TOP2 complex (Minotti et al., 
2004). Doxorubicin is the most efficiency inhibitor of TOP2 (Granados-Principal et al., 2010). 
There is a low level of TOP2 activity after doxorubicin treatment indicating a mechanism of 
doxorubicin-resistance (Williams et al., 2007). The impairment in DNA synthesis reduces the 
cell capacity for repairing damaged DNAs, which leads to the apoptosis of tumour cells.  
Doxorubicin can also target important genes such as protein 53 (p53) gene which plays 
an important role in cells apoptosis (Quiles et al., 2002). p53 is a tumour suppressor that 
responds to various stress signals by initiating cell-cycle arrest, senescence and apoptosis. 
Over half of human tumours are found the p53 gene mutations, and the interactions between 
p53 and Ataxia telangiectasia mutated (ATM) kinase pathways can explain some of the 
tumour suppressive activities of p53 (Vasseur et al., 2011). Doxorubicin has been shown to 
activate p53 and ATM and increase Bax/Bcl-2 ratio, resulting in DNA damage and cell 
apoptosis (Yoshida et al., 2009). In addition, the anti-apoptotic heme oxygenase-1 was 
decreased by doxorubicin (Bernuzzi et al., 2009). Doxorubicin also increases release of other 
apoptosis factors such as FAS Ligand (Granados-Principal et al., 2010) (Poulaki et al., 2001). 
There is evidence that doxorubicin activated matrix metalloproteinase (MMP) which plays a 
major role in cell proliferation/apoptosis and is involved in the release of apoptotic FAS 
Ligands (Bai et al., 2004; Kizaki et al., 2006). 
 
1.2.2. Oxidative stress 
Doxorubicin can cause cellular oxidative stress by inducing the production of 
oxidative free and the generation of highly mutagenic species in its metabolism process which 
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affect DNA synthesis cell apoptosis directly and/or indirectly and (Granados-Principal et al., 
2010; Mataix et al., 2006; Minotti et al., 2004; Quiles et al., 2002) (see below). For example, 
doxorubicin induced hydrogen peroxide generation which leads to activation of p38 and c-Jun 
N-terminal kinases (JNKs), and Mitogen-activated protein kinases (MAPKs) activation 
(Ghosh et al., 2011).  
 
1.3. Doxorubicin-induced cardiotoxicity 
One of the major concerns of clinical use of doxorubicin and other anthracyclines for 
cancer treatments is its toxicity (Simunek et al., 2009). Doxorubicin-induced toxicity usually 
appears few weeks and months after its administration, including cardiovascular insufficiency, 
hepatic insufficiency, renal insufficiency, and nervous system injury (Granados-Principal et 
al., 2010). The symptoms of doxorubicin-induced toxicity include nausea, vomiting, 
myelosuppression, and arrhythmia etc. (Gaitanis and Staal, 2010).  
Cardiac cells are active and more sensitive to changes of oxidant environments thus 
sensitive to cellular damage induced by doxorubicin. A systematic review indicates that 
comparing anthracycline and non-anthracycline treatments, cardiotoxicity of anthracycline is 
increased by 5.43 fold (Smith et al., 2010). 
Doxorubicin-induced cardiotoxicity can be diagnosed by evaluation of cardiac functions 
(e.g. decreased heart weight and ratio), Electrocardiography (changed ST and QRS-intervals) 
(Huang et al., 2004) and monographic changes of cardiac tissues (e.g. myocardial fibers injure, 
mitochondrial damage, cytoplasmic vacuolisation, and lysosomes increase) (Gaitanis and 
Staal, 2010). Moreover, the concentration of glutamate oxaloacetic transaminase, lactate 
dehydrogenase (LDH), and creatinine phosphokinase enzyme in serum are increased by 
doxorubicin (Zhang et al., 2011). 
The current approach for limiting the doxorubicin-induced cardiotoxicity is to use 
improved formulations such as pegylated liposomal doxorubicin (Livi et al., 2011), This can 
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limit the cardiac damages to certain degree but still cannot totally protect doxorubicin-induced 
cardiotoxicity. In some cases, other agents are used such as dexrazoxane. However those 
agents are generally still not satisfactory and more effective agents are needed.  
 
1.3.1. Mechanisms of doxorubicin-induced cardiotoxicity 
In general, the mechanism of doxorubicin-induced cardiotoxicity is similar to that of its 
anti-cancer actions as mentioned above. Studies have shown several pathways are involved in 
doxorubicin-induced cardiotoxicity, including oxidant stress, DNA damage, mitochondria 
dysfunction and other mechanisms (Chen et al., 2007). More recently, L-arginine - NO 
pathway has been recognised as playing an important role in doxorubicin-induced 
cardiotoxicity (Mukhopadhyay et al., 2009).  
 
1.3.1.1. Reactive oxidative species and ion metabolism 
There is strong evidence that doxorubicin induces the production of reactive oxidative 
species (ROS) (such as superoxide) (Mukhopadhyay et al., 2009), which in turn affects DNA 
synthesis, lipid peroxidation and malondialdehyde (MDA) production and other cellular 
processes (Ascensao et al., 2011). The mechanism of doxorubicin induced reactive oxygen 
species (ROS) production directly links to the process of its cellular metabolism. Superoxide 
onion (O2
-) is produced from O2 when doxorubicin was metabolised from quinone to 
semiquinone (Bachur et al., 1978). The semiquinone reacts with oxygen in cytoplasm to 
produce doxorubicin-quinone. Thus, superoxide onion is continuously produced in the 
presence of doxorubicin. Doxorubicin also interacts with formaldehyde to form a new toxic 
compound (Simunek et al., 2009). Various NAD(P)H-dependent reductases are believed 
playing important role in this process, including cytochrome P-450 reductase (Dudka et al., 
2005). Superoxide production leads to generation of other ROS such as hydrogen peroxide 
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(H2O2) and hydroxyl radical (OH
-). ROS can leads to mitochondria damage and cell death 
(Figure 2) (Ascensao et al., 2011).  
On the other hand, studies from quelamycin, a synthetic tri-ferric derivative from 
doxorubicin (Brugarolas et al., 1978), found that it caused acute and chronic iron toxicity 
(Brugarolas et al., 1979). Superoxide onion reacts with Fe3+ to form ferritin (Bachur et al., 
1978), through Fenton reaction and Haber-Weiss reaction (Minotti et al., 1999), which is 
considered as the original source of lipid peroxidation protein sulfhydryl oxidation genomic 
and mitochondrial DNA damage (Simunek et al., 2009). The following illustrate the process 
of Fenton reaction and Haber-Weiss reaction (Simunek et al., 2009). 
Fenton reaction: Fe3+ + O2
.- → Fe2+ + O2; 
 Fe2+ + H2O2 → Fe
3+ + OH. + OH- 
Haber-Weiss reaction: O2
- + H2O2 → O2 + OH
. + OH- 
 
1.3.1.2. NO and peroxynitrite 
L-arginine-NO pathway plays a fundamental role in cell functions. Endogenous NO is 
synthesized from L-arginine via NO synthase (NOS), which has three different isoforms, 
neuronal NO synthase (nNOS), inducible NO synthase (iNOS) and endothelial NO synthase 
(eNOS). In accordance with the time of genes were cloned, they are also named as NOS I 
(type 1 NOS, nNOS), NOS II (type 2 NOS, iNOS) and NOS II (type 3 NOS, eNOS) (Pacher 
et al., 2007). nNOS and eNOS are Ca2+-dependence enzyme (Radomski et al., 1990). nNOS 
produces NO in nervous tissue, it is mainly related to neural activities (Steinert et al., 2010). 
eNOS produces NO in blood vessels and mainly regulates endothelial vascular functions 
(Dias et al., 2011). iNOS is Ca2+-independence enzyme (Radomski et al., 1990), it is mainly 
involved in inflammatory mechanisms (Xia and Vanhoutte, 2011). Proinflammatory 
cytokines elicit iNOS induction thus increase NO productions in variety of cells (Nathan and 
Xie, 1994). One of the important molecules derived from NOS is peroxynitrite which is a 
product of NO and superoxide (NO+O2
- → ONOO-) (Mukhopadhyay et al., 2007). 
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Peroxynitrite has been involved in pathological mechanisms of many diseases and 
conditions, including doxorubicin-induced cardiotoxicity (Mukhopadhyay et al., 2007). 
Peroxynitrite was considered with more oxidant activity than hydrogen peroxide 
(Mukhopadhyay et al., 2007). Studies have demonstrated that doxorubicin increased NO and 
superoxide productions, which may lead to the formation of peroxynitrite. More importantly, 
the effect of doxorubicin was inhibited by the peroxynitrite scavenger MnTBAP 
(Mukhopadhyay et al., 2009). 
 
1.3.2. Mitochondria function 
Mitochondria play important roles in cell metabolism and apoptosis. Studies indicate 
that doxorubicin causes the myocardial mitochondria damage by increasing ROS production 
and reducing antioxidant defences capacity (Carvalho et al., 2009; Sardao et al., 2008; 
Wallace, 2003; Wallace, 2007). There is evidence that physical exercise in cardiac tolerance 
of animals treated with acute and sub-chronic doses of Doxorubicin modulates some 
important cardiac defence systems to antagonize the toxic effects caused by doxorubicin, 
including antioxidant capacity, the overexpression of heat shock proteins and other anti-
apoptotic proteins, highlighting the importance of cardiac mitochondrial-related mechanisms 
in the process. The affected targets/signalling mechanisms include Bax/Bcl-2, extracellular 
signal-regulated kinases (ERKs), p53, mitochondria membrane potential, caspase-9 caspase-3 
(Liu et al., 2008a). Poly(ADP-ribose) polymerase (Mukhopadhyay et al., 2009), NADPH 
oxidase p22(phox), p47(phox), p67(phox) (Arozal et al., 2010), pro-apoptotic proteins such as 
cytochrome C, SMAC/DIABLO and mitochondrial permeability transition pore (MPTP) 
(Ascensao et al., 2011).  
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1.3.3. Other mechanisms 
Doxorubicin can modify intercellular calcium (Ca2+) metabolism, resulting in changed 
Ca2+ levels and unbalance response of myotubes (Mataix et al., 2006). Studies indicate that 
the chronic cardiotoxicity induced by doxorubicin related to decreased calcium/calmodulin-
dependent protein kinase II mRNA (Little et al., 2009). In addition, activation of adenosine 
A(3) receptor restored Ca2+ homeostasis and prevented mitochondrial damage induced by 
doxorubicin in rats (Emanuelov et al., 2010).  
The metabolism of prostaglandins is another possible mechanism of doxorubicin-induce 
cardiotoxicity (Granados-Principal et al., 2010). Recent study showed that l-carnitine reduced 
cardiomyocytes ROS production and apoptosis induced by doxorubicin, at the same time, the 
prostacyclin (prostaglandin I2) production was increased (Chao et al., 2011). Moreover, when 
prostacyclin was increased, peroxisome proliferator-activated receptor (PPAR)-α expression 
was increased in NRK-52E cells in vitro at the same time, the protective of doxorubicin-
induced apoptosis was recorded (Lin et al., 2007a). There is evidence that the prostaglandin I2 
pathway and PPAR-α maybe play important roles in mechanisms of doxorubicin (Chao et al., 
2011).  
A recent study investigated the role of endocannabinoid in doxorubicin-induced 
cardiotoxicity in mice (Mukhopadhyay et al., 2011). It was found that the doxorubicin-
induced myocardial oxidative/nitrative stress (increased 4-hydroxynonenal, protein carbonyl, 
and nitrotyrosine levels and decreased glutathione content) were enhanced in fatty acid amide 
hydrolase (FAAH, the main endocannabinoid anandamide-metabolizing enzyme) knockout 
mice which showed increased doxorubicin-induced mortality and cardiac dysfunction 
compared to their wild type. The effects of doxorubicin in FAAH knockouts were attenuated 
by cannabinoid (CB) receptor 1 antagonists. Furthermore, anandamide enhanced cell death in 
human cardiomyocytes pretreated with FAAH inhibitor and enhanced sensitivity to ROS 
generation in inflammatory cells of FAAH knockouts. These results suggest that FAAH (CB1 
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receptor) plays a key role in controlling the tissue injury associated with acute 
oxidative/nitrative stress (Mukhopadhyay et al., 2011).  
 
1.3.4. Strategies in reducing doxorubicin-induced cardiotoxicity 
Given the significance of doxorubicin therapies in treating cancers, it is important to 
reduce or limit the doxorubicin-induced cardiotoxicity. Numerous studies have been carried 
out in the past to search effective agents/drugs to reduce doxorubicin toxicity. Many 
compounds have been tested, including natural products. The main approach is based our 
current understanding the mechanism of doxorubicin-induced cardiotoxicity. The current 
strategies include three different directions: 
1. Searching low toxicity doxorubicin derivatives. Many new derivatives of doxorubicin 
have been synthesized and tested for higher chemotherapy index but lower cardiotoxicity than 
doxorubicin (Ludke et al., 2009). Around 2000 analogues have been obtained from 
doxorubicin and daunorubicin, although only a few have been tested for their activities. Some 
of these derivatives showed a significant low toxicity (Weiss, 1992). One of the most 
successful approached to reduce doxorubicin-induced cardiotoxicity but do not decrease its 
antitumor ability is to replace free doxorubicin with liposomal formulations to target certain 
tumour cells directly (Menna et al., 2010). The rational is that the size of liposomal 
formulation is small enough to go into the discontinuous endothelium of tumours, but not 
cross of endothelial lining of coronary vessels (Minotti et al., 2004). Comparing liposomal 
and non-liposomal doxorubicin, liposomal doxorubicin-induced cardiotoxicity was lower than 
non-liposomal doxorubicin (Odd ratio, 0.18 95% confidence interval: 0.08, 0.38) (Smith et al., 
2010). 
2. Developing a cocktail therapy of combining doxorubicin with other anticancer drugs to 
reduce the dosage and treatment exposure of doxorubicin and improve its therapeutic index 
against different kinds of tumours (Ludke et al., 2009). Studies have been conducted for 
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combining doxorubicin with vincristine, procarbazine, cisplatin, and cyclophosphamide 
(Chambers et al., 1996; Zancanella et al., 2006).  
3. Developing adjuvant therapies such as antioxidants and chelators (Ludke et al., 2009). 
For example: chelating agents, such as ethylenediaminetetraacetic acid (EDTA, Figure 3) 
could bind Fe2+ to prevent its oxidation by doxorubicin (Witiak et al., 1977) (Figure 2). 
Razoxane (ICRF-159) and dexrazoxane (Zinecard, ICRF-187), are isomers of EDTA and 
have been used against doxorubicin-induce cardiotoxicity (Kik and Szmigiero, 2006; 
Simunek et al., 2009). Figure 4 illustrates a hypothesis of cardioprotective action of 
dexrazoxane, based on the formation of ADR-925, which is an iron scavenger, competitively 
binding free ferrous (Fe2+) and ferric (Fe3+) (Buss and Hasinoff, 1993; Diop et al., 2000; 
Hasinoff, 1993). Dexrazoxane significantly reduced 79% doxorubicin- and epirubicin-induced 
cardiotoxicity (Odd ratio, 0.21 95% confidence interval: 0.13, 0.33) (Smith et al., 2010).  
Certain natural products have properties of chelating iron (e.g. Flavonoids: monoHER, 
catechin, quercetin, genistein) (Granados-Principal et al., 2010). In addition, it is based the 
role of oxidative stress in doxorubicin-induced cardiotoxicity, many natural antioxidants such 
as vitamins, lycopene, coenzyme Q and extracts of traditional herbal medicines have been 
tested. However, the extent of these studies has not been extensively reviewed and relevant 
mechanisms have not been elucidated. Thus, further study of actions of natural products and 
related mechanisms may help to understand the mechanism involved and for further 
development of novel agents for limiting or preventing doxorubicin-induced cardiotoxicity.  
 
Figure 3. Structures of EDTA and ICRF-159. 
NHN
N NH
O
O
O
O
ICRF-159 EDTA Chelates Fe2+ 
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Figure 4. Mechanism of ICRF187. Adopted from Schroeder et al., 2008. Dexrazoxane 
metabolises, via DHPase, to form the open-ring intermediates, Form 1 and Form 2, which 
were further metabolised to ion-chelating compound ADR-925 via DHOase. 
 
1.4. Aims of thesis 
As mentioned above, there is a clinical need for development of new therapies to manage 
doxorubicin-induced cardiotoxicity as the current treatments are still not satisfactory 
(Granados-Principal et al., 2010). Based on current understanding of mechanisms of 
doxorubicin induced cardiotoxicity and the progress on natural product research, it is 
important to evaluate the current evidence of actions of natural products on doxorubicin 
cardiotoxicity, and further to study the effects and mechanisms of certain natural compounds 
such as Salvia miltiorrhiza (Danshen) which has long been used for treating various 
cardiovascular diseases such as myocardial injury or myocardial infarction (Ji et al., 2007).  
Thus, the general objective of the project is to conduct a literature review on studies on 
actions of natural products on doxorubicin induced cardiotoxicity, and further to design and 
test the effects of an active compound of Danshen and its derivatives on doxorubicin-induced 
cardiotoxicity and to investigate the possible association of their effects with endogenous NO 
pathways, given the recent evidence demonstrating its importance in doxorubicin-induced 
cardiotoxicity.  
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The specific aims of the project are:  
1. To conduct a literature review on actions of natural products on doxorubicin-induced 
cardiotoxicity; 
2. To test the effects of tanshinone IIa, an active compound of Danshen, on doxorubicin-
induced cardiotoxicity in cultured rat cardiomyocytes, rat H9C2 cells; 
3. To test the effects of tanshinone IIa related synthetic compounds on doxorubicin-
induced cellular toxicity in H9C2 cells; 
4. To investigate the possible relationship of the actions of these compounds to 
endogenous NO pathway by measuring NO production in H9C2 cells. 
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2.1. Introduction 
As mentioned in the Chapter 1, doxorubicin is an important anticancer drug, thus to 
limit or prevent its toxicity in particular cardiac toxicity will be important for its clinical 
applications. One of the current strategies for developing new or complementary therapies for 
limiting or preventing doxorubicin-induced cardiotoxicity is to study antioxidants and 
chelators (Ludke et al., 2009). The goal is to develop an effective therapeutic agent to reduce 
doxorubicin-induced cardiotoxicity without reducing its anti-cancer actions (Granados-
Principal et al., 2010). In this regards, natural products may play an important role as it has 
been well known that many important therapeutic drugs are derived from natural sources. For 
example, taxol, an important anticancer drug is a plant alkaloid (Chirgwin and Chua, 2011). 
Aspirin, morphine and artemisinin (also known as qinghaosu) are also derived from plants 
(Chida, 2011; Johannesson, 2000; Li and Wu, 1998). Many natural products have been shown 
with inhibitory actions on doxorubicin-induced cardiotoxicity which are related to their 
antioxidant actions (Granados-Principal et al., 2010).  
Chinese herbal medicines are a well-developed traditional medicine system involving 
using acupuncture and other therapies in particular medicinal herbs to treat various clinical 
conditions. Chinese herbal medicines have been widely used in China and other countries, and 
some Chinese herbal medicines have been investigated on doxorubicin-induced cardiotoxicity, 
although the extent of such studies has not been systematically reviewed. Thus, it is necessary 
to conduct a literature review on actions and mechanisms of natural products, including 
Chinese herbal medicines on doxorubicin-induced cardiotoxicity.  
The present review has two main goals: (1) to report the latest findings regarding the 
molecular mechanisms of doxorubicin toxicity; (2) to update our understanding of the role of 
natural antioxidants in preventive therapy against doxorubicin-induced toxicity. This review 
provides new evidence for the chemoprevention of doxorubicin toxicity, making use of 
natural antioxidants in particular vitamin E, vitamin C, coenzyme Q, carotenoids, vitamin A, 
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flavonoids, polyphenol, resveratrol, antioxidant from virgin olive oil and selenium and offers 
new insights into the molecular mechanisms of doxorubicin toxicity with respect to DNA 
damage, free radicals and other parameters. 
 
2.2. Method 
Extensive literature search was conducted using the available electronic databases, 
including PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) (via EBSCO), Cochrane Central Register of Controlled 
Trials (CENTRAL), EMBASE (via Science Direct), China National Knowledge Infrastructure 
(CNKI)，Chinese Scientific Journals Full text Database (CQVIP) and Wanfang. The search 
key words include, anthracycline, doxorubicin, cardiotoxicity, toxicity, heart, herb(s), plants, 
antioxidants, Chinese herbal medicine, extracts, vitamins, etc and combinations. There is no 
language restriction. All studies in basic science and/or clinical research have been included.  
 
2.3. Actions of natural products on doxorubicin-induced cardiotoxicity 
There have been extensive studies on the actions of a range of natural products on 
doxorubicin-induced cardiotoxicity. These products include not only crude plant extracts but 
also purified molecules isolated or derived from the natural sources.  
 
2.3.1. Naturally derived chelating agents 
Ion plays an important role in doxorubicin-induced cardiotoxicity (see Chapter 1). Thus, 
finding agents with strong ion chelating property is an effective approach for developing 
agents to protect doxorubicin-induced cardiotoxicity. A number of natural derived compounds 
(Figure 5) have been tested and shown to be effective in vitro and/or in vivo (Table 2).  
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Figure 5. Structures of natural derived ion chelating agents. 
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Table 2. Effects of natural derived ion chelating agents on doxorubicin-induced cardiotoxicity. 
Classification Compound Experiment Dose/Concentration Consequence Reference 
Flavonoids monoHER In vivo, A2780, 
OVCAR-3, mice 
100-500mg/kg Decreased Electrocardiography 
changes by doxorubicin 
(Bast et al., 2007) 
 Quercetin Mice, in vivo 50 to 200mg/kg Decreased LDH & iNOS activity, 
NO and MDA concentration, p53 
expression* 
(Pei et al., 2007) 
    Increased SOD activity and heart 
functions 
 
Catechins Catechin Rat, in vivo 20- 200mg/kg Increased cardiac function (Kozluca et al., 
1996b) 
 EGCG*  38-100µM Decreased ROS production and 
cardiomyocytes apoptosis 
(Li et al., 2010) 
 
* LDH: lactate dehydrogenase, MDA: malondialdehyde, EGCG: Epigallocatechin gallate. 
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Catechins, including catechin, epigallocatechin gallate (EGCG), epigallocatechin (EGC, 
were extracted from green tea (Seeram et al., 2003). Studies in vivo in rats have demonstrated 
that 20 or 200mg/kg catechin for 8 weeks reduced the doxorubicin (3mg/kg)-induced 
cardiotoxicity, measured by the body and heart weight, heart rate and Q-T intervals (Kozluca 
et al., 1996a). Studies in vitro showed that catechin inhibited tissues mutagenicity (Gentile et 
al., 1998). Other studeis showed that 40µg/ml tea polyphenols or 10µg/ml EGCG in BEL-
7404/Adr cells for 24 hours reduced the IC50 of doxorubicin from 10.35µg/ml to 2.35µg/ml 
(tea polyphenols) and 5.45µg/ml (EGCG), respectively (Wei et al., 2003). Similar results 
showed that combination of ECG or EGCG with doxorubicin increased actions of 
doxorubicin and its therapeutic index (Liang et al., 2004), as well as reduced doxorubicin 
resistance which may involve protein kinase C (Stammler and Volm, 1997). Moreover, 
combination 38-100µM EGCG with 1µM doxorubicin decreased ROS production and 
apoptosis in myocardial cells (Li et al., 2010).  
Many plants contain flavonoids. Flavonoids such as monoHER, catechins, quercetin and 
genistein have been shown with actions of anti-doxorubicin induced toxicity (Granados-
Principal et al., 2010). For example, quercetin (50 to 200mg/kg, intraperitoneal injection) in 
mice in vivo increased the activity of SOD and decreased doxorubicin (20mg/kg)-induced 
arrhythmia which is associated with the reduction of activity/production of LDH, iNOS/NO, 
MDA, and p53 (Pei et al., 2007). Another study showed that pre-treatment with 100-
500mg/kg monoHER (7-monohydroxyethylrutoside) protected doxorubicin-induced 
cardiotoxicity (e.g. ST-interval changes) in vivo in mice (Bast et al., 2007). Pre-treatment 50 
and 100µM monoHER in human xenografts ovarian and breast cell lines increased IC50 of 
doxorubicin in OVCAR-3, but decreased in MCF-7 (Bast et al., 2007). However, in a clinical 
study involving 8 patients, monoHER at a total dose of 300mg/m2 did not show a protection 
against doxorubicin-induced heart damage (Bruynzeel et al., 2007). 
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2.3.2. Antioxidants 
Many natural antioxidants have been demonstrated with protective actions on 
doxorubicin-induced cardiotoxicity (Granados-Principal et al., 2010). The structures of some 
of these compounds are shown in Figure 6. The antioxidant capacity of some common natural 
compounds is as follows: lycopene > vitamin E > α-carotene > β-cryptoxanthin > zeaxanthin 
= β-carotene > lutein (Sahin et al., 2010).  
 
Figure 6. The structures of some antioxidant compounds. 
 
2.3.2.1. Vitamins 
Certain vitamins have been extensively studied, such as vitamin B6, C, and E (Table 3). 
Vitamin B6 (12.5-100mg/kg b.w.) was found to inhibit the clastogenicity induced by 
doxorubicin in rat bone marrow cells (Takeuchi et al., 2008). In an in vivo study in rats, 
pretreatment vitamin C (100mg/kg/week for 3 weeks) did not protect doxorubicin-induced 
cardiotoxicity (doxorubicin 1.5mg/kg/week for 3 weeks) (Injac et al., 2009). However, a 
separate study found a mixture of vitamin C (250mg/kg/day) and E (400IU/kg/day) protected 
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against doxorubicin-induced toxicity (Santos et al., 2007). Pre-treatment with vitamin C 
(30µM) and vitamin E (100µM) also increased expressions of p-glycoprotein (P-gp) and HIF-
1α in DU-145Nox1 cells, but not in DU-145 cells. Vitamin C or E alone did not increase 
multidrug resistance-1 (MDR-1) mRNA expression (Wartenberg et al., 2005). In clinical 
studies, VCE (vitamin C 500mg tablet and vitamin E 400mg gelatin capsule i.v. day 1, every 
3 weeks for six cycles) increased activities of endogenous SOD, catalase, glutathione-S-
transferase and glutathione reductase, and glutathione level but decreased the levels of MDA 
and DNA damage (Suhail et al., 2011).  
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Table 3. Effects of vitamins on doxorubicin-induced cardiotoxicity. 
Compounds Experiment Treatments Dose/Concentration Consequence Reference 
Vitamin C Rat, in vivo pretreatment 100mg/kg No protective effect of 
doxorubicin-induced 
cardiotoxicity 
(Injac et al., 2009) 
Vitamin C & 
E Mixture 
Rat, in vivo After 
doxorubicin 
supplement 
Vitamin C 
(250mg/kg/day) & E 
(400 IU/kg/day) 
Increased: survival and 
biochemical parameters 
(Santos et al., 2007) 
 Clinical combination Vitamin C 500mg & E 
400mg 
Decreased the levels of MDA and 
DNA damage 
(Suhail et al., 2011) 
    Increased activities of SOD, 
catalase, glutathione-S-transferase 
and glutathione reductase, level of 
glutathione 
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2.3.2.2. Coenzyme Q  
Coenzyme Q (CoQ, ubiquinone) is an important endogenous antioxidant. A systematic 
review of indicates that CoQ protected against doxorubicin-induced cardiotoxicity in children 
(Bryant et al., 2007). Studies using cultured myocytes from mice found that 120μM CoQ10 
increased cardiac cell activity which was reduced by doxorubicin, and 50mg/kg CoQ10 in 
mice in vivo increased mice survival rate (Conklin, 2005). In a clinical study, CoQ10 
(1mg/kg/day) significantly increased patients heart function (determined by 
Electrocardiography) and decreased side effects (diarrhea and stomatitis) of doxorubicin 
(Tsubaki et al., 1984). 
 
2.3.2.3. Theanine  
Theanine is a glutamic acid analogs commonly presented in green tea (JUNEJA et al., 
1999). Studies have demonstrated that theanine reduced doxorubicin-induced toxicity in heart 
and liver, with decreased cardiac lipid peroxide level and increased glutathione peroxidise. 
Theanine increased concentration of doxorubicin in tumour cells and normal tissues, but 
without affecting its toxicity in normal cells (Sadzuka et al., 1996) However, later study found 
that theanine decreased the level of doxorubicin in the liver, although the activity of CYP was 
not affectd (Sadzuka et al., 2006). The antioxidant property of theanine may be related to its 
capability of transferring 2H+ from the NH2 group of the pyrimidine ring and H
+ from the 
thiazole ring to reactive substrates (Lukienko et al., 2000). Moreover, in mice in vivo study, 
theanine significantly increased doxorubicin anticancer activity. The effect of doxorubicin 
was increased 2.1-fold, concentration of doxorubicin in ehrlich ascites carcinoma was 
increased 2.9-fold; simular result was obtained in M5076 ovarian sarcoma-bearing mice 
(Sugiyama and Sadzuka, 2003). 
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2.3.2.4. Carotenoids 
Carotenoids, such as lycopene and β-carotene are widely present in natural products, 
(Granados-Principal et al., 2010). These compounds have an unsaturated carotenoid long 
chain structure which is heat resistant. Lycopene (non-provitamin A) has a strong antioxidant 
property and has been shown to protect against doxorubicin-induced toxicity in vitro and in 
vivo (Table 4).  
Studies have demonstrated that lycopene (1.7 and 3.5mg/kg, i.p.) decreased doxorubicin 
(15mg/kg) induced heart injury and serum creatine phosphokinase (CPK) levels in mice 
(Karimi et al., 2005). Lycopene (5mg/kg) increased total antioxidant capacity in vivo and 
prevented oxidation of phosphatidylcholine liposomes in vitro in heart tissues (Ferreira et al., 
2007b). Monograph study showed lycopene could reduced cardiomyocytes apoptosis in rats 
in vivo, although it did not prevent the left ventricular functions failure appearing which 
induced by doxorubicin (Anjos Ferreira et al., 2007). Another study demonstrated that 
pretreament with lycopene (4mg/kg) in rats, reduced doxorubicin-induced changes in MDA 
and glutathione concentrations in heart and kidneys. Post-treatment with lycopene normalised 
changes in catalase and levels of plasma creatinine and urea but changes in activities of 
glutathione peroxidase (GSH-Px) were not affected (Yilmaz et al., 2006). Lycopene did not 
affect the anticancer of doxorubicin in canine osteosarcoma cells in vitro (Wakshlag and 
Balkman, 2010). On the other hand, lycopene reduced formations of doxorubicin semiquinone 
free radicals and myocardial MDA production, but increased the activities of SOD and GSH-
Px in myocardial tissues (Lu et al., 1996).  
β-carotene (1-4mg/mL) has also been shown to inhibit doxorubicin (0.125mg/ml) 
induced free-radical generation and genotoxicity (Dias et al., 2009).  
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Table 4. Effects of lycopene on doxorubicin-induced cardiotoxicity. 
Compound Species Treatment Dose/Concentration Consequence Reference 
Lycopene Mouse, in vivo Combination 
and therapy 
1.5-1.7mg/kg Decreased heart injury (Karimi et al., 2005) 
 Rat, in vivo Combination 5mg/kg Decreased DNA damage  (Ferreira et al., 2007a) 
 Rat, in vivo Pretreament 4mg/kg Decreased MDA and 
glutathione 
(Yilmaz et al., 2006) 
β-carotene Rat, in vivo and in vitro   10 or 30mg/kg/day Anti cardiotoxicity and 
free radicals 
(Lu et al., 1996) 
 Drosophila 
melanogaster 
Combination 1-4mg/mL Decreased genotoxicity (Atessahin et al., 2006; 
Dias et al., 2009) 
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2.3.2.5. Resveratrol 
Resveratrol (3,4’,5-trihydroxy-trans-stilbene) is found in many species/sources (Gupta 
et al., 2011), such as Momordica charantia (Yu et al., 2007), grapes (Moran et al., 2009), and 
wine (Mahyar-Roemer and Roemer, 2001). It has a range of bioactivities including antibiotics, 
against ROS and cardiomyocytes protective action (Gupta et al., 2011).  
Studies have found that pre-treated H9C2 cells with resveratrol 100µM for 3 days 
increased the cells viability, and antioxidant enzymes, which was accompanied by increased 
resistance to oxidative and electrophilic cell injury (Cao and Li, 2004). Separate studies in rats 
showed that resveratrol (30 or 120mg/kg/day i.p. for 3 days) reduced doxorubicin (10mg/kg)-
induced myocardial injury, and ROS generation, the effect was associated with NO pathway 
(Wang et al., 2007). Resveratrol (1-10µM) reduced doxorubicin-induced bradycardia and QTc 
interval prolongation in mice and increased the anticancer effect of doxorubicin in human 
uterine cancer cells (Rezk et al., 2006). It is important to note that resveratrol can induce 
apoptosis in doxorubicin-resistant cells, but not normal cells (Feng et al., 2006), thus it can 
potentially reduce doxorubicin-induced toxicity without affecting or even benefit the 
therapeutic actions of doxorubicin (Dudka et al., 2005). The mechanism of actions of 
resveratrol is not clear, but may be related to its effects on NO pathways (Olukman et al., 
2009). A number of resveratrol derivatives have been developed, such as trans-3 E-3-[(4-
hydroxy-3-methoxyphenyl)methylene]-4-(3,5-dihydroxyphenyl)-5-(4-
hydroxyphenyl)tetrahydro-2-franone and Resveratrol trans-dehydrodimer (Yu et al., 2007); 
(E)-3,5-difluoro-40-acetoxystilbene and (E)-3,5-di(trifluoroacetylamino)-40-fluorostilbene 
(Moran et al., 2009). 
 
2.3.2.6. Curcumin  
There are some controversial reports on actions of curcumin. An in vitro study showed 
that pre-treatment of H9C2 cells with 5-15µM curcumin enhanced expressions of Bax/Bcl-2 
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ratio, caspase-8, caspase-9 and ROS formation induced by 3µM doxorubicin (Hosseinzadeh et 
al., 2011). In contrast, a synthetic of curcumin: HO-3867 was shown with anticancer effect 
and protective actions against doxorubicin-induced cardiotoxicity (Dayton et al., 2011). 
Combination 5µM HO-3867 with 2.5µM doxorubicin significantly increased cell viability in 
H9C2 cells. An early study in vivo showed that curcumin (200mg/kg) decreased doxorubicin-
induced lipid peroxidation and changes in serum creatine kinase (CK) and LDH, and 
increased endogenous SOD level in rats (Venkatesan, 1998).  
 
2.3.2.7. Oleuropein 
Oleuropein, is found in olives, olive oil, and the leaves and small branches of the olive 
tree (Granados-Principal et al., 2010). Studies have demonstrated that oleuropein (100 or 
200mg/kg) decreased doxorubicin (20mg/kg) induced changes in serum levels of CPK, CPK-
MB, LDH, Aspartate aminotransferase (AST) and Alanine aminotransferase, which was 
associated with decreased lipid peroxidation, PCs content, NT concentration and iNOS 
induction in myocardial tissue, and normalised cardiac metabolism activity (e.g. myocardial 
acetate and succinate) (Andreadou et al., 2009; Andreadou et al., 2007). Studies on olive oil 
indicate that virgin olive oil may have a better result (Mataix et al., 2006). 
 
2.3.2.8. Minerals 
Dietary selenium (0.1mg/kg, single dose) increased total antioxidant activity, 
glutathione concentration, and GSH-Px and catalase activities which were decreased by 
doxorubicin (10mg/kg) in vivo, it also decreased generation of ROS in cardiac issues (Danesi 
et al., 2006).  
A mixture of vitamins (vitamins C, E, and β-carotene) and minerals (copper, selenium, 
and zinc) has been shown to inhibit doxorubicin-induced genotoxicity and ROS production 
(Costa and Nepomuceno, 2006). 
Cur
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2.3.3. Other compounds 
 
Figure 7. The structures of other compounds.  
 
Inhibition of cannabinoid 1 (CB1) receptor by morphine, anandamide, and ketotifen 
may be involved in the anti-doxorubicin-induced cardiotoxicity actions of these agents. (Hiley, 
2009; Mukhopadhyay et al., 2007). Morphine has been shown to inhibit doxorubicin-induced 
generation of ROS and activations of caspase-3, cytochrome c, and Bax/Bcl-2 (Lin et al., 
2007b). Morphine (10mg/kg/day) improved cardiac function damaged by doxorubicin 
(1.25mg/kg/day) in rats (Kelishomi et al., 2008). Similarly, anandamide (30mg/kg) improved 
cardiac dysfunction induced by doxorubicin (10mg/kg) in rat in vivo (Hydock et al., 2009) 
and ketotifen increased the survival rate and prevent cardiotoxicity induced by doxorubicin 
(15mg/kg) in mice in vivo (Bartoli Klugman et al., 1988).  
 
2.3.4. Agents derived from food and traditional medicines  
2.3.4.1. Plant extracts 
Green tea extracts - Green tea extract contains certain active ingredients (such as 
catechin, EGCG, ECG, theanine) which are iron chelating agents and with antioxidant 
activities as mentioned above (Seeram et al., 2003). In vitro studies indicate that green tea 
extract (10-50µg/ml) prevented 10µM doxorubicin-induced cardiotoxicity in cardiomyocytes 
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sarcoma 1.5-fold in mice in vivo (Sugiyama and Sadzuka, 2003). A recent study demonstrates 
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that green tree extract (200mg/kg/day) inhibited doxorubicin-induced spermatogenic disorders 
(Sato et al., 2010).  
Tomato extract - Tomato extract (1.2 and 2.4 g/kg, i.p.) decreased serum CPK-MB and 
cardiac injury induced by doxorubicin (15mg/kg) (Karimi et al., 2005). This can be explained 
by the active compounds in tomato extract such as lycopene, as mentioned above (Sahin et al., 
2010). A study found that tomato-oleoresin (5mg/kg) protected DNA fragments in rat 
myocardial cells induced by doxorubicin (4mg/kg) (Ferreira et al., 2007a).  
Garlic extract - Studies in vivo in mice using aged garlic extract have demonstrated that 
treatment with aged garlic extract 6 times per week for 40 days improved cardiac functions 
which was damaged by doxorubicin (1.5mg/kg three times per week), which was associated 
with inhibition of lipid peroxidation and restored muscle and mitochondria functions (Kojima 
et al., 1994). Similarly, rats were administrated with freshly prepared garlic homogenate 250 
and 500mg/kg/day for 30 day, then with 30mg/kg doxorubicin, showed an increased 
endogenous antioxidants and decreased TNF-α expression in cardiac tissues, compared with 
the control (Mukherjee et al., 2003). In vivo studies found that xanthine oxidase activities and 
serum cardiac enzymes LDH and CPK, malondialdehyde (MDA) activities were decreased 
and the SOD levels and heart functions were increased by aged garlic extract in rats, 
(Alkreathy, Damanhouri et al.). In a cases report, a 50 years old patient with breast carcinoma 
and doxorubicin treatment, showed an improved heart function when was given a garlic pearl 
(Das and Poudel, 2006). Garlic contains certain antioxidant active ingredients (Dwivedi et al., 
1998). A volatile organosulfur compound identified in garlic inhibited vinca alkaloid-induced 
P-gp expression in tumours ,which may help to improve doxorubicin index (Arora et al., 
2004).  
Soybean extract - soybean extract contains isoflavones, which have been shown to 
have a cardiac protective action against doxorubicin-induced toxicity on myocyte (Ma et al., 
2004). 
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Danshen extract - Danshen has long been used for treating myocardial injury and 
myocardial infarction as well as hepatocellular toxicity (You et al., 2007). Studies in vitro 
have demonstrated that Danshen extract (20 and 100mg/kg, oral supplied for rat) inhibited 
doxorubicin-induced cardiac and hepatic toxicity determined by histopathology, and 
myocardial GSH-Px activity and SOD activities (You et al., 2007). The action of Danshen 
extract is related to the active compounds involved (see below).  
Ginkgo biloba extract – G. biloba is a well know traditional Chinese medicinal herb. A 
commercial extract of G. biloba (EGb 761) has been developed and extensively studied, EGb 
761 has been shown to be a free radical scavenger (Bekerecioglu et al., 1998). G. biloba 
extract (150mg/kg), did not affect the anticancer effect of doxorubicin (1.5mg/kg) but 
inhibited cardiac lipoperoxidation and pathological changes induced by doxorubicin (Agha et 
al., 2001). Another study demonstrated that G. biloba extract inhibited cardiac damages and 
dysfunction induced by doxorubicin and increased myocardial ATP content and gene 
expression of ghrelin mRNA (Xu et al., 2009).  
Terminalia arjuna extract – T. arjuna at 15µg/ml decreased ROS generation and 
cardiotoxicity induced by doxorubicin (Reddy et al., 2008). Similarly to G. biloba, in vivo 
experiments demonstrated that T. arjuna extract reduced cardiac lipid peroxidation and free 
radical formation, as well as morphological changes (Singh et al., 2008). 
Panax notoginseng extract - It has been demonstrated that pre-treatment mice with P. 
notoginseng saponins (100mg/kg) significantly protected the doxorubicin-induced 
cardiotoxicity as evidenced from improved ventricular contractile function, lower levels of 
serum LDH, CK and CK-MB, minimal morphological changes in hearts, and normalization of 
myocardial SOD, GSH-Px and catalase activities (Liu et al., 2008b). 
Angelica sinensis extract – A. sinensis has been widely used to treat cardiovascular and 
cerebrovascular diseases in China. Oral administrated A. sinensis (15g/kg orally daily for 4 
weeks) decreased the myocardial injury induced by doxorubicin through improving heart 
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performance as evidenced from normalization of antioxidative activity and serum AST, 
preventing loss of myofibrils as well as improving arrhythmias and conduction abnormalities 
(Xin et al., 2007b).  
Lycium barbarum extract - Xin et al (2007) studied the effect of an aqueous extract of 
L. barbarum on doxorubicin-induced cardiotoxicity, by measuring cardiac electrocardiograph, 
heart antioxidant activity, serum levels of CK and AST and histopathological change. It was 
found that doxorubicin caused arrhythmias and conduction abnormalities in 
Electrocardiography (increased QT and ST intervals and ST elevation) and a decrease of heart 
antioxidant activity, an increase of serum CK and AST, as well as myocardial lesions. L. 
barbarum extract (25mg/kg, p.o.) to rats daily for 3 weeks, prevented the loss of myofibrils 
and improved the heart function as evidenced from lower mortality (13%), normalization of 
antioxidative activity and serum AST and CK (Xin et al., 2010; Xin et al., 2007a). Similar 
effects have been reported for L. barbarum polysaccharides with further evidence for 
increasing SOD and GSH-Px activity and decreased the MDA level of heart tissues, 
indicating it act through suppressing oxidative stress (Xin et al., 2011). 
Phyllanthus urinaria extract - Studies in vitro using H9C2 cardiac myoblasts have 
demonstrated that an ethanolic extract of P. urinaria L inhibited doxorubicin-induced lipid 
peroxidation and caspase-3 activation induced by doxorubicin (Chularojmontri et al., 2005), 
Endogenous antioxidant enzymes such as total glutathione, catalase and SOD activities, 
which were retained in the presence of doxorubicin, were increased by the extract. In addition, 
similar to ascorbic acid and N-acetylcysteine, the P. urinaria extract inhibited the nuclear 
factor кB (NFкB) activation (through кB transcription factor assay), indicating that P. 
urinaria protects against doxorubicin-induced cardiotoxicity through multiple pathways 
mainly as an antioxidant (Chularojmontri et al., 2005). Further studies indicate that the 
cytoprotective mechanism of the extract involved the glutathione-S transferase (GST) in 
cardiac H9C2 cells, as it regulated the nuclear localization of GST protein without 
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significantly affecting the enzymatic activity. It was suggested that the extract had a 
cytoprotective effect by reducing cellular levels of doxorubicin with enhanced nuclear 
localization of GST protein in myocardial cell (Chularojmontri et al., 2009). 
Glycyrrhiza uralensis extract - A recent study in mice in vivo demonstrated that G. 
uralensis extract protected doxorubicin-induced cardiotoxicity by decreasing levels of serum 
LDH and CK-MB, improved heart morphology and increased GSH-Px activity and 
glutathione level (Zhang et al., 2011). 
Astragalus extract - Su et al., (2009) studied the effect of Astragalus root extract on 
doxorubicin-induced cardiotoxicity in rats in vivo. Rats were given doxorubicin 
intraperitoneally (12mg/kg) for 2 weeks. Astragalus was given 1 day before the onset of 
doxorubicin administration (orally, 3.3 or 10g/kg/day for 50 days). Rats treated with 
doxorubicin showed a significant inhibition of cardiac diastolic function accompanied by the 
presence of ascites, reduction in body weight and heart weight as well as survival rate 
compared to the controls. Moreover, SERCA2a mRNA and protein expressions in hearts were 
downregulated. The impaired cardiac function was improved in both doses of Astragalus, 
with the high dose of Astragalus also attenuated the changes of SERCA2a expression in 
injured hearts. It has been suggested that Astragalus may improve cardiac function by 
upregulation of SERCA2a expression (Su et al., 2009). A separate study on renal toxicity 
found that Astragalus aqueous extract inhibited reduction of renal cortex CAT, GSH-Px and 
SOD activities induced by doxorubicin (You et al., 2011). 
Panax ginseng - You et al., (2005) showed a cardioprotective effect of P. ginseng in 
vivo in rats. P. ginseng (cumulative dose, 150g/kg) decreased the mortality, ascites and lipid 
peroxidation induced by doxorubicin (15mg/kg) which was associated with increase in 
myocardial cells GSH-Px, macromolecular biosynthesis and SOD activities (You et al., 2005). 
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2.3.4.2. Active compounds 
 
Figure 8. The structures of some antioxidant compounds. 
 
Danshen - The main active compounds of Danshen include lipid soluble compounds 
such as tanshinones (eg tanshinone I, tanshinone IIa, cryptotanshinone) and water soluble 
compounds such as salvianolic acid A and B. There is evidence that these active compounds 
have potent antioxidant activities. For example, salvianolic acid A has been shown in vitro to 
inhibit oxidative radical formation (e.g. H2O2) and mitochondria dysfunction intoxicated in 
cardiac cells induced by doxorubicin (Lin et al., 1992). Studies in vivo demonstrated that 
salvianolic acids (40mg/kg for 3 days) reduced doxorubicin-induced (15mg/kg) toxicity, 
including elevation of body weight and heart weight/tibia length ratio, decrease of CK, 
improvement of electrocardiography and heart vacuolation, which are associated with 
antioxidative effects of salvianolic acids (Jiang et al., 2008). Similarly, tanshinone IIa has 
been demonstrated to inhibit doxorubicin-induced ROS production and apoptosis, as well as 
reduction of the ratio of Bcl-2/Bax in cultured cardiomyocytes (Gao et al., 2008). In vivo 
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weight caused by doxorubicin, which was associated with increased endogenous antioxidant 
enzymes, such as SOD, GSH-Px and catalase and an inhibition of doxorubicin-induced lipid 
peroxidation (Zhou et al., 1999). In vitro studies also confirmed the activity of sodium 
tanshinone IIa sulphonate in inhibition of doxorubicin-induced mitochondrial lipid 
peroxidation and swelling, and in scavenging doxorubicin semiquinone free radical formation 
in heart homogenate (Zhou et al., 1999). A recent study using primary cultured neonatal rat 
cardiomyocytes indicates that tanshinone IIa (1 and 3μM) inhibited doxorubicin-induced ROS 
generation, reduced the quantity of cleaved caspase-3 and cytosol cytochrome c, and 
increased Bcl-xl expression, resulting in protecting cardiomyocytes from doxorubicin-induced 
apoptosis, which was at least partly through activation of Akt-signaling pathways (Akt 
phosphorylation) (Hong et al., 2010). 
Schisandrin B - In vivo studies in mice and rats have demonstrated that Schisandrin B 
protected against doxorubicin (25mg/kg, i.p.)-induced release of cardiac enzymes into serum, 
the formation of MDA, the activation of MMP, the structural damage in the left ventricles and 
the mortality rates. It maintained the cardiomyocyte glutathione and enhanced the activities of 
SOD, GSH-Px, glutathione reductase, and glutathione transferase (Li et al., 2007).  
Naringenin-7-O-glucoside - Naringenin-7-O-glucoside is the main active constituent of 
Dracocephalum rupestre Hance. Studies in vitro demonstrated that naringenin-7-O-glucoside 
enhanced cardiomyocyte proliferation relative to that of doxorubicin and increased the 
expressions of heme oxygenase-1 (HO-1) and Bcl-2 proteins but decreased mRNA 
expressions of caspase-3 and caspase-9 in cardiomyocytes, which are related to its protection 
on doxorubicin-induced cardiotoxicity (Han et al., 2008). 
 
2.3.4.3. Herbal formulations 
A number of traditional herbal formulations have been demonstrated with protective 
actions on doxorubicin-induced cardiotoxicity (Table 5). 
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Buzhong Yiqi Decoction - Studies in vivo in rats demonstrated that this formulation 
decreased doxorubicin-induced myocytes fiber swelling and fracture, myocardial cells deaths 
was decreased, as well as increased antioxidant ability in heart tissues (Wang et al., 2011). 
Buzhong Yiqi Decoction contains the following herbs: Radix astragali preparata, Radix 
codonopsitis, Largehead atractylodes, Angelica, Cimicifuga foetida, Radix bupleuri, 
Pericarpium citri reticulatae (Zhao et al., 2011). 
Sini decoction powder - A study in vivo in rats demonstrated that Sini decoction 
powder (3.7g/kg/day, oral, for 3 weeks), significantly decreased doxorubicin-induced 
cardiomyocyte apoptosis and Bid protein expression. The decrease of Bcl-xl protein 
expression and mRNA ratio of Bcl-xl/Bcl-xs by doxorubicin were also increased by this 
formulation (Zhao et al., 2009). Sini decoction contains Aconitum carmichaeli, Zingiber 
officinale and G. uralensis (Tan et al., 2011). 
Shenqi Fuzheng injection - Wang et al., (2006) studied the clinical efficacy and 
adverse reactions of standard chemotherapy protocols (e.g. Chemotherapy-CHOP) with or 
without the combination of Shenqi Fuzheng injection in moderate malignant non-Hodgkin's 
lymphoma patients, and the incidence rate of adverse reaction as leukopenia, neurotoxicity, 
and cardiac toxicity were lower in the Shenqi Fuzheng injection group than those in the 
control group (Wang et al., 2006). Similar result was obtained from Bo et al., (2007) study, 
which found that the life quality of patients with mammary cancer treated with Shenqi 
Fuzheng injection was improved compared with the control. The neurotoxicity and cardiac 
toxicity were lower in Shenqi Fuzheng injection group than the control group (Bo et al., 2007). 
Shenqi Fuzheng injection contains Radix, Astragali and Radix codonopsis (Dong et al., 2010).  
Sheng Mai San - Since Sheng Mai San has been used clinically for treating cardiac 
diseases thus it has a potential for protecting or treating doxorubicin-induced cardiotoxicity 
(Rong, 1989). An early study failed to demonstrate the protective actions of Sheng Mai 
injection on doxorubicin-induced cardiotoxicity in doxorubicin in cultured myocardial cells 
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(Cai, 1991). Recent study in vivo in rat demonstrated that an oral preparation of Sheng Mai 
San (daily for 30 days with cumulative dose, 150g/kg), before or concurrent with doxorubicin) 
significantly attenuated doxorubicin (15mg/kg)-induced inhibitions of nucleic acid and 
protein synthesis /increase in lipid peroxidation. The myocardial level of GSH-Px and SOD 
protein were increased while the concentration of MDA in heart was decreased. This indicates 
that this formulation may be partially protective against doxorubicin-induced cardiotoxicity 
(You et al., 2006). Sheng Mai San contains P. ginseng, Radix ophiopogonis and Fructus 
schisandra (You et al., 2006). 
Xinshuaikang - This formulation contains Radix ginseng, Aconifum carmichaelii, 
Ligustici wallichii, Semen Lepidii seu Descurainiae, etc. Experimental studies in rabbit 
demonstrated that it inhibited doxorubicin-induced heart failure and body weight reduction, 
which was associated with reduction of plasma level of atrial natriuretic polypeptide (Jin et al., 
1996).  
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Table 5. Effects of traditional herbal formulations on doxorubicin-induced cardiotoxicity. 
Formulation  Experiment Dose/Concentration Treatment  Consequence Reference 
Buzhong Yiqi 
Decoction 
Rat, in vivo Low/high Dose Pretreatment Decreased myocardial fiber swelling and fracture, and 
cardiomyocyte apoptosis 
(Wang et al., 
2011) 
    Increased heart tissues antioxidant capacity  
Sini Decoction 
 
Rat, in vivo 3.75 g/kg/d Post-
treatment 
Decreased cardiomyocyte apoptosis, Bid protein 
expression 
(Zhao et al., 
2009) 
    Increased Bcl-xl expression, Bcl-xl/Bcl-xs mRNA ratio  
Shenqi Fuzheng 
injection 
Clinical   Post-
treatment 
Increased patients life quality (Bo et al., 
2007) 
    Decreased leukopenia, neurotoxicity, and cardiotoxicity (Wang et al., 
2006) 
Sheng-mai-san Rat, in vivo 150g/kg Post-
treatment 
Decreased cardiomyocyte apoptosis, ascites (You et al., 
2006) 
    Increased survival rate  
 Myocardial cell, 
in vitro 
30-300mg/L  No protective effect (Cai, 1991) 
 Clinical   Decreased doxorubicin-induced cardiotoxicity (Rong, 1989) 
Xinshuaikang Rabbit, in vivo Low/high Dose Post-
treatment 
Decreased atrial natriuretic polypeptide level (Jin et al., 
1996) 
    Increased Body weight and heart function,  
 
* BUN: blood urea nitrogen, CCR: creatinine clearance rate, TGF-β: protein transforming growth factor-β, TGF-β receptor I or II (TbetaR I or II), 
CTGFp: connective tissue growth factor protein, CTGF mRNA, PDGF-BB: platelet-derived growth factor-BB, PDGF-BB mRNA, Scr: proteinuria, 
serum creatinine. 
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2.4. Comparison of anti-cardiotoxicity and anticancer actions of natural products 
One of the important questions in developing agents for precenting or limiting 
doxorubicin-induced cardiotoxicity is to not affecting the anti-cancer actions of doxorubicin. 
Certain studies have been carried out to compare the effects of natural products on 
doxorubicin-induced cardiotoxicity and its anticancer actions (Table 6). 
A number of compounds/products have been shown in vitro or in vivo to protected 
doxorubicin-induced cardiotoxicity without affecting the anti-cancer actions of doxorubicin. 
These include such as G. biloba extract (Agha et al., 2001), A. sinensis extract (Xin et al., 
2007b), P. notoginseng extract (Liu et al., 2008b), L. barbarum polysaccharides (Xin et al., 
2011), G. uralensis extract, and P. ginseng (You et al., 2005), as well as some purified 
compounds such as salvianolic acid A (Lin et al., 1992), schisandrin B (Li et al., 2006) , 
tanshinone IIa (Hong et al., 2010) and lycopene (Wakshlag and Balkman, 2010). 
On the other hand, some natural products have been shown to reduce doxorubicin’s 
anticancer activity. For example, studies in mice in vivo showed combination 250mg/kg 
vitamin C reduced doxorubicin anticancer activity in xenografts K562 cells (Heaney et al., 
2008). Some compounds were found in vitro to increase the doxorubicin-induced 
cardiotoxicity, such as curcumin (Hosseinzadeh et al., 2011). Using vitamin C or E alone did 
not show protective effect in vivo (Injac et al., 2009), even vitamin C and E would decrease 
doxorubicin anticancer capacity in vitro (Wartenberg et al., 2005). When combination vitamin 
C and E after doxorubicin treatment in patients, it dramatically decreased doxorubicin-
induced oxidative (Suhail et al., 2011).  
There are limited clinical studies on comparison of effects of natural products on 
doxorubicin-induced cardiotoxicity and its anti-cancer actions. Thus have a potential for 
developing new therapeutic agents for protecting or limiting doxorubicin-induced 
cardiotoxicity. Based on the fact that some of natural compounds such as tanshinones have 
been used clinically for treating cardiovascular conditions or anticancer applications, it is 
 41 
important to conduct further study to understand the mechanisms of actions of these 
compounds. 
 
Table 6. Comparison of effects of natural products on anti-cardiotoxicity and anti-cancer 
actions of doxorubicin. 
Product/compound Cardiotoxicity Anticancer 
action 
Reference 
Green tea Extracts Decreased Increased (Sugiyama and 
Sadzuka, 2003) 
EGCG Decreased Increased (Liang et al., 2004) 
ECG Decreased Increased (Liang et al., 2004) 
Tea polyphenols Decreased Increased (Wei et al., 2003) 
Theanine Decreased Increased (Sugiyama and 
Sadzuka, 2003) 
Tanshinone 
Microemulsion 
- Increased (Fan et al., 2004) 
Tanshinone I - Increased (Lee et al., 2010) 
Tanshinone IIa Decreased Increased (Lee et al., 2010) 
Cryptotanshinone - Increased (Lee et al., 2010) 
Dihydrotanshinone - Increased (Lee et al., 2010) 
Vitamin C No effect Decreased or 
no effect  
(Wartenberg et al., 
2005) 
Vitamin E No effect No effect (Wartenberg et al., 
2005) 
Vitamin C and E Decreased No effect (Suhail et al., 2011) 
Lycopene Decreased No effect (Wakshlag and 
Balkman, 2010) 
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Chapter 3.  
Effect of tanshinone IIa and synthetic derivatives on doxorubicin-
induced toxicity in H9C2 cells 
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3.1. Introduction 
Danshen, the dried root of Salvia miltiorrhiza, is one of most widely used traditional 
Chinese herbal medicines for treating various cardiovascular conditions, such as cardiac 
ischemia and stroke (Adams et al., 2006; Zhou et al., 2005). The active ingredients of 
Danshen include lipid-soluble components such as cryptotanshinone, tanshinone I and 
tanshinone IIa and water-soluble components such as danshensu, and salvianolic acid B (Zhou 
et al., 2005). Pharmacological research indicates that these active compounds have a range of 
pharmacological actions, including vasodilatation and inhibitions of ischemia injuries, 
especially in cardiac tissues (Zhou et al., 2005). Recently Danshen has been cultivated in 
Australia as a quality medicinal plant for herbal farming indicating its potential development 
in Australia (Li et al., 2009a; Li et al., 2009b; Li et al., 2011). 
The cardioprotective actions of Danshen have been well demonstrated. For example, 
Danshen has been showed to inhibit myocardial ischemia and reperfusion injury in isolated 
hearts (Wang et al., 2009). The actions of Danshen may involve its actions on generation of 
free radicals and protection of myocardial mitochondrial membranes (Zhao et al., 1996). 
Additionally tanshinone IIa inhibited H2O2-induced cardiomyocyte apoptosis in vitro and in 
vivo, an effect associated with increased scavenging of oxygen free radicals, prevention of 
lipid peroxidation and upregulation of the Bcl-2/Bax ratio (Fu et al., 2007). Tanshinone IIa 
has also been showed to inhibit miR-1 and reduce the myocardial infarction by acting on p38 
MAPK pathways (Zhang et al., 2010).  
Based on the pharmacological actions of Danshen compounds, it is logical to predict 
that Danshen active compounds may be useful in reducing or limiting the cardiotoxicity 
induced by doxorubicin. In fact it has been found that oral administration of Danshen (20 and 
100mg/kg) 30 days before the administration of doxorubicin (3mg/kg, i.p.) significantly 
attenuated doxorubicin-induced changes in DNA synthesis and myocardial antioxidants and 
lipid peroxidation (You et al., 2007). Similar effects have been demonstrated for tanshinone 
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IIa (Gao et al., 2008). The actions of tanshinone IIa may be mediated by inhibiting ROS 
generation and changes in caspase-3, cytosol cytochrome c, Bcl-xl markers involving Akt-
signaling pathways (Hong et al., 2010). However, the mechanism of actions of tanshinone IIa 
has still not been elucidated. For example, recent studies demonstrated an important role of 
NO and peroxynitrite in doxorubicin-induced cardiac cell death, with findings that 
doxorubicin and peroxynitrite-induced apoptosis/necrosis were inhibited by peroxynitrite 
scavengers and selective iNOS inhibitors as well as cell-permeable SOD, but not by xanthine 
oxidase or NADPH oxidase inhibitors, indicating peroxynitrite is a major trigger of 
doxorubicin induced cell death both in vivo and in vivo (Mukhopadhyay et al., 2009). It is not 
clear if the cardioprotective actions of tanshinone IIa on doxorubicin-induced cardiotoxicity 
are related to the activities of endogenous NO pathway or the productions of cellular NO. 
Given the therapeutic benefit of targeting the relevant pathways in the development of new 
agent treating doxorubicin-induced cardiotoxicity, it is important to investigate the 
relationship of actions of tanshinone IIa and NO production in cardiac cells. In addition, a 
series of new compounds derived from tanshinone IIa have been developed at RMIT, it is 
important to investigate the effects of these new compounds on doxorubicin induced cell 
toxicity and relevant relationship to endogenous NO production in cardiac cells.  
 
3.2. Methods 
3.2.1. Materials and reagents 
Doxorubicin ∙ HCL (Purity >98%), L-NIL (L-N6-(1-Iminoethyl)lysine hydrochloride) 
(purity >98%), L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride) (Purity >99%), 
MnTBAP (Purity >98%), L-arginine (purity >99.9%), DAF-2 (Purity ≥98%), DAF-2 DA 
(Purity ≥98%), Spermine NONOate (Purity ≥97%) were obtained from Sapphire Bioscience 
Pty. Ltd.. Sulphuric acid (Purity ≥99.999%), potassium iodide (Purity ≥99.5%), Dimethyl 
sulfoxide (DMSO) (Purity ≥99.7%) were obtained from (Sigma-Aldrich Pty. Ltd.). 
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Tanshinone IIa (Purity >95%) was obtained from National Institutes for Food and Drug 
Control, China. Synthetic AFC compounds (purity >98%) were supplied by A/Prof Helmt 
Hugel from Chemistry, School of Applied Sciences, RMIT University. MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was supplied by Invitrogen Australia 
Pty Limited. 
All reagents were dissolved in DMSO or sterile pure water (Milli-Q® Integral Water 
Purification System) for stock solutions. Stock solutions of drugs were stored at -20oC and 
further dilutions were made for subsequent experiments and the final concentrations of each 
agent is described in below. DAF-2 and DAF-2 DA were avoided light and used immediately 
after preparation. 
 
3.2.2. Cell culture  
H9C2 cell line was derived from embryonic rat heart (Kimes and Brandt, 1976). The 
reason to choose H9C2 cells in this study is due to that H9C2 cell line has been widely used 
an accepted in vitro model to study the effects of pathological conditions such as ischemia and 
doxorubicin, on the heart (Sardao et al., 2007). H9C2 cells show electrical and hormonal 
signaling pathway of cardiac tissues and with ability to differentiate from mono-nucleated 
myoblasts to myotubes, and express calcium channel proteins, myogenic transcription factors 
and other proteins (Hescheler et al., 1991; Sardao et al., 2007). Nevertheless, H9C2 cells are 
not human cells. They are also different from primary cardiomyocytes which are specialised 
and non-proliferative Future studies using human cardiac cells/tissues and in vivo will help to 
establish/confirm if similar mechanisms are involved in human. 
H9C2 cells were obtained from American Type Culture Collection (ATCC) (Distributor: 
Cryosite Distribution Pty. Ltd.) and stored in Liquid nitrogen. Cell culture experiments were 
conducted according to a standard procedure in PC2 laboratories at RMIT University, 
Bundoora campus, using established facilities including biohazard II cabinets and CO2 
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incubators. Briefly, cells were cultured in Dulbecco's modified Eagle's medium (DMEM), 
with fetal bovine serum (FBS, final concentration is 10%), and antibiotic (Final 
concentrations: penicillin 100units/ml and streptomycin 100µg/ml). The culture medium was 
changed every two or three days. Cell passages (11 to 40) were used for experiments. Cells 
were subcultured at 1:4 when cells reached 70-80% confluent. Subculture was made by 
raising the cells first with culture medium then adding 2.0 to 3.0ml of Trypsin-EDTA solution 
to detach the cells (usually within 5 to 15 minutes). Cells were then suspended in 6.0 to 8.0ml 
of DMEM medium and 5ml aliquots of the cells suspension were transferred to 3 or 4 new 
25cm2 flasks. Cells were stored in 2.5ml tubes in liquid nitrogen. When needed, cells were 
thawed quickly in a water bath (37°C) and then each tube cells were set at the 25cm2 flask 
with 5ml culture medium. 
Cell numbers were counted using Trypan-Blue method (L'Ecuyer T et al., 2011). Briefly, 
500µl of cells suspension was mixed with 500µl Trypan-Blue (1:2 dilutions). The cell mixture 
was placed into the counting area of a haemocytometer and counted under a microscope (10X 
objective) and counted (4x16 corner squares). Live cells were not stained (while dead cells 
were stained) by Trypan-Blue. Cell concentrations were calculated by dividing the total 
number of counted cells by 4 and multiplying by 2, caused by 4 corners of haemocytometer 
and 1:2 Trypan-Blue dilutions. 
 
3.2.3. Cell viability assay 
The Cell toxicity was assessed by cell viability using MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay. This assay was firstly developed in 1983 (Mosmann, 
1983) based on the change of water soluble MTT to an insoluble formazan (Berridge and Tan, 
1993; Liu et al., 1997; Vistica et al., 1991), which could be detected by microplate absorbance 
reader at 540nm. The sensitivity of the assay was approx 106 cells per well (Molecular Probes, 
2002). Briefly, cells in 96 wells plate (1x104cells per well) were treated with MTT and then 
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detected using the BMG polarstar OPTIMA multidetection microplate reader (540nm).  
Protocol: 10µl of the 12mM MTT was added to each well 96 wells plate, including a 
negative control (10µl of the MTT solution added to 100µl of medium alone). Cells were 
incubate at 37°C for 4 hours, and then removed all but 25µL of medium from the wells. 
Added 50µL of DMSO to each well to dissolve the formazan and mixed thoroughly with the 
pipette, incubated at 37°C for 10 minutes. Absorbance was read at 540nm (Carmichael et al., 
1987).  
Phenol red free medium were supplied by Invitrogen Australia Pty. Ltd. with HEPES as 
an analyze medium; trypsin-EDTA solution contained 2.5g/l trypsin (1:250) and 0.38 g/l 
EDTA•4Na in Hanks' Balanced Salt Solution, contained phenol red, without CaCl2, MgCl2 • 
6H2O, and MgSO4 • 7H2O. Fetal bovine serum tested for the ability to support the expansion 
and clonal enumeration (colony forming unit fibroblast assay) of mesenchymal stem cells. 
Endotoxin level: ≤50 EU⁄ml (levels routinely ≤10 EU⁄ml). Haemoglobin level: ≤25mg⁄dl. 
Antibiotic penicillin-streptomycin liquid contained 10,000 units of penicillin and 10,000µg of 
streptomycin per 1ml utilizing penicillin G (sodium salt) and streptomycin sulphate in 0.85% 
saline.  
Dulbecco’s Phosphate Buffered Saline (DPBS) 10X solution, Dulbecco’s Phosphate 
Buffered Saline with MgCl2 and CaCl2, Trypan-Blue were supplied by Sigma-Aldrich Pty. 
Ltd.. 
 
3.2.4. Measurement of intracellular NO by fluorescence dye 
The method was as previously described (Leikert et al., 2001). The principal of the 
method is that the fluorescence probe 4,5-diaminofluorescein (DAF-2) reacts with NO to form 
triazolofluorescein (DAF-2 T), which can be detected at 515 nm with fluorescence under 
visitable light, excitation is 495 nm (Leikert et al., 2001). Different DAF-2 analogues have 
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been developed including DAF-2 diacetate (DAF-2 DA) which is membrane permeable. Once 
inside the cell, DAF-2 DA is reduced to DAF-2 (Kojima et al., 1998). (Figure 9) 
Cells (1x104 cells per well in 96wells plate) was incubated with 10µM DAF-2 DA for 
60 minutes. Fluorescence was detected under a fluorescence microscopy (Nikon Fluorescence 
Microscopy, excitation: 460-490nm, emission: 510-560nm) or BMG polarstar OPTIMA 
multidetection microplate reader (excitation at 485nm and emission at 520nm).  
For establishing a standard curve, Spermine NONOate (0.01µM to 20µM) was used as a 
NO donor (its half-life in 0.1M phosphate buffer (PH 7.4) at 37°C is t1/2 (39min). DAF-2 or 
DAF-2 DA solution (protected from light and stored in 4°C) was used immediately after 
preparation.  
 
Figure 9. Principle of intracellular NO Measurement by DAF-2 DA (Kojima et al., 1998). 
Lipophilic, non-fluorescent DAF-2-DA permeates the cell membrane and is then hydrolyzed 
by cytosolic esterases to the weakly fluorescent probe DAF-2. The presence of NO radicals 
transforms it to the strongly fluorescent triazole DAF-2 T. 
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3.2.5. Measurement of NO by inNO Sensor 
 NO concentration in the cell medium was also measured as the final product of NO, 
nitrite, using inNO Sensor system (inNO-T system Innovative Instruments, Inc) which his 
specific for measuring free radical NO (Xingyu et al., 2011). Nitrite was reduced to free 
radical NO by iodide and sulphuric acid as illustrated below (Reginald H. Garrett, 2005):  
1. NO3
-+2H++2e-→NO2
-+H2O 
2. NO2
-+I-+2H+→NO+I+H2O 
Amino-600 sensor was calibrated with potassium nitrite standard solution, and 0.1M 
sulphuric acid and 0.05M potassium iodide. The selection of frequency of the notch filter was 
at 50Hz and the current range was at 2,500,000pA. Different volumes (5, 10, 20, 30, 40, 50, 
70, and 100µl respectively) of potassium nitrite standard solution (100µM) were added to the 
20ml stirred calibration solution. And NO signal was recorded.  
 
3.2.6. Statistical analysis 
Data were expressed as means and standard error of means (s.e.m.). Repeated 
experiments were conducted for each assay as indicated in the result section. For MTT assay, 
cell availability was expressed as % of the control group. For NO assays, NO fluorescence 
intensity or NO signal on mV were recorded. Statistical differences between different groups 
were tested using the statistical software SPSS 17.0 (Statistical Package for the Social 
Sciences) one-way ANOVA, with probability (p) value less than 0.05 as indication of 
statistical significant difference. 
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3.3. Results 
3.3.1. Doxorubicin-induced cell toxicity 
Cell viability determined by MTT assay. Incubation of H9C2 cells with either vehicle 
for 24 hours did not significantly affect the cell viability (Figure 10) (p>0.05, one way 
ANOVA).  
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Figure 10. Effect of vehicles on cell viability of H9C2 cells. H9C2 cells were treated with 
vehicles, which were DMSO (final concentration 0.1%) or water (add additional 1% pure 
water to the cell culture medium) for 24 hours. Cell viability was determined by MTT assay. 
Data were expressed as means and s.e.m., n=11-20 indicates the number of repeated 
experiments, each with triplicate determinations; SPSS, one way ANOVA. 
 
Figure 11 shows the effect of doxorubicin on H9C2 cell viability. Doxorubicin (0.1µM- 
30µM) caused a concentration-dependent cell death after 24 hours incubation. For example, at 
1µM, the cell viability was decreased to 62% of the control; at 10µM, it was reduced to 42%. 
However, at 0.1µM it did not significantly reduce the cell viability after 24 hr incubation. For 
the subsequent to experiments the concentration of doxorubicin was fixed at 1µM.  
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Figure 11. Effect of different concentrations of doxorubicin on cell viability of H9C2 cells. 
Cell viability was determined by MTT assay. Incubation time 24 hours. Data were expressed 
as means and s.e.m., n=6 for repeated experiments, each with triplicate determinations. ** 
p<0.01, *** p<0.001, compare with control; SPSS, one way ANOVA. 
 
The effect of different incubation time on doxorubicin induced cell death was also 
investigated. As shown in Figure 12 Cells viability was significantly reduced after 6hr 
incubation with doxorubicin. At 48 hr incubation the cell death rate was about 92%, compared 
with the control. For the subsequent experiments doxorubicin was incubated for 24 hour.  
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Figure 12. Effect of different incubation time of 1µM doxorubicin on cell viability of H9C2 
cells. Cell viability was determined by MTT assay. Incubation time 6-48 hours. Data were 
expressed as means and s.e.m., n=3 for repeated experiments, each with triplicate 
determinations. *** p<0.001, compare with control; SPSS, one way ANOVA. 
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3.3.2. Effects of different drugs on doxorubicin-induced cell toxicity 
3.3.2.1.  NO synthase inhibitor L-NIL 
Incubation of H9C2 cells with the selective iNOS inhibitor L-NIL (100-1000µM) up to 
48 hours did not significantly affect the cell viability (Figure 13). 
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Figure 13. Effect of L-NIL on cell viability of H9C2 cells. Cell viability was determined by 
MTT assay. Incubation 48 hours respectively. Data were expressed as means and s.e.m., n=3, 
for repeated experiments, each with triplicate determinations; SPSS, one way ANOVA. 
 
Incubation of L-NIL 100µM, 300µM, and 1000µM with doxorubicin at 1µM 
significantly protected of cell death induced by doxorubicin (p<0.01 ANOVA (Figure 14). 
For example, the cell viability was 79% with L-NIL 100µM, compared that of doxorubicin 
alone (59%). 1000µM L-NIL increased the cell viability to 83%, which however did not reach 
the statistical significance. 
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Figure 14. Effect of L-NIL on 1µM doxorubicin-induced cell death in H9C2 cells. Cell 
viability was determined by MTT assay. Incubation time 24 hours. Data were expressed as 
means and s.e.m., n=6 in control, n=3-6 for repeated experiments, each with triplicate 
determinations. ### p<0.001, compare with control; ** p<0.01, compare with doxorubicin 
group; SPSS, one way ANOVA. 
 
3.3.2.2.  Cell permeable SOD mimetic MnTBAP  
Low concentrations of MnTBAP (10 and 30µM) did not affect the cell viability up to 48 
hours incubation. However, high concentration of MnTBAP (100µM) slightly but 
significantly increased the cell viability (109%, 48 hours incubation) (Figure 15). 
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Figure 15. Effect of cell permeable SOD mimetic MnTBAP on cell viability in H9C2 cells. 
Cell viability was determined by MTT assay. Incubation time was 48 hours, respectively. 
Data were expressed as means and s.e.m., n=3 indicates the number of repeated experiments, 
each with triplicate determinations. ## p<0.01, compare with control; SPSS, one way 
ANOVA. 
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Combination of MnTBAP (10-100µM) with 1µM doxorubicin significantly inhibited 
the cell death caused by doxorubicin, with, for example, the cell viability at 74% and 81%,for 
10 and 30µM MnTBAP. However, the cell viability of MnTBAP 100µM plus doxorubicin 
1µM was reduced to 64% (Figure 16). 
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Figure 16. Effect of cell permeable SOD mimetic MnTBAP on 1µM doxorubicin-induced 
cell death in H9C2 cells. Cell viability was determined by MTT assay. Incubation time was 
24 hours. Data were expressed as means and s.e.m., n=3-6 indicates the number of repeated 
experiments, each with triplicate determinations. ## p<0.001, compare with control, ** 
p<0.01, compare with doxorubicin; SPSS, one way ANOVA. 
 
3.4. Effects of tanshinone IIa on doxorubicin-induced cell toxicity 
Incubation of H9C2 cells for 24 hours with low concentrations of tanshinone IIa (0.1-
3µM) did not significantly affect the cell viability of H9C2 cells. However, high 
concentrations of tanshinone IIa (10 and 30µM) significantly decreased the cell viability 
(Figure 17).  
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Figure 17. Effect of different concentrations of tanshinone IIa (0.1-30µM) on cell viability in 
H9C2 cells. Cell viability was determined by MTT assay. Incubation time was 24 hours. Data 
were expressed as means and s.e.m., n=3-6 indicates the number of repeated experiments, 
each with triplicate determinations. ** p<0.01, *** p<0.001, compare with control; SPSS, one 
way ANOVA. 
 
Similarly, incubation of cells for 48 hours with low concentrations of tanshinone IIa 
(0.3-3µM) did not significantly affect the cell viability of H9C2 cells. However, high 
concentrations of tanshinone IIa (10µM) significantly decreased the cell viability (Figure 18).  
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Figure 18. Effect of different concentrations of tanshinone IIa (0.1-30µM) on Cell viability in 
H9C2 Cells. Cell viability was determined by MTT assay. Incubation time was 48 hours. Data 
were expressed as means and s.e.m., n=3 for separate each with triplicate determinations. ### 
p<0.001, compare with control; SPSS, one way ANOVA. 
 
Low concentration 0.1µM and 0.3µM tanshinone IIa significantly inhibited 
doxorubicin-induced cell death after 24 hours incubation, with the cell viability at 71% and 
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74%, respectively compared with that of doxorubicin group alone (57%). High concentration 
of tanshinone IIa (30µM) significantly decreased the cell viability to 23% compared to 
doxorubicin group (Figure 19). 
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Figure 19. Effect of different concentrations of tanshinone IIa (0.1-30µM) on 1µM 
doxorubicin-induced cell death in H9C2 cells. Cell viability was determined by MTT assay. 
Incubation time was 24 hours. Data were expressed as means and s.e.m., n=3-12 for separate 
experiments, each with triplicate determinations. ### p<0.001, compare with control; * 
p<0.05, *** p<0.001 compare with doxorubicin; SPSS, one way ANOVA. 
 
In some experiments, H9C2 cells were pre-incubated with tanshinone IIa first for 24 
hours then were incubated with doxorubicin for another 24 hours. Under this condition, 
Tanshinone IIa 0.3µM and 1µM significantly increased the cell viability. A high 
concentration of tanshinone IIa (10µM) significantly decreased the cell viability compared to 
doxorubicin alone (Figure 20). 
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Figure 20. Effect of pre-incubation of tanshinone IIa (0.1-30µM) on 1µM doxorubicin-
induced cell death in H9C2 cells. Cell viability was determined by MTT assay. Incubation 
time was 24 hours pre-incubation of tanshinone IIa, then was 24 hours incubation of 
doxorubicin. Data were expressed as means and s.e.m., n=3-9 for separate experiments, each 
with triplicate determinations. ### p<0.001, compare with control; * p<0.05, compare with 
doxorubicin; SPSS, one way ANOVA. 
 
In separate experiments, H9C2 cells were firstly incubated with doxorubicin first for 24 
hours then were incubated with tanshinone IIa for another 24 hours. Under this condition, 
tanshinone IIa 0.3µM did not significantly improve the changes of cell viability induced by 
doxorubicin alone (Figure 21). 
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Figure 21. Effect of 0.3µM tanshinone IIa on pre-incubation of 1µM doxorubicin-induced 
cell toxicity in H9C2 cells. Cell viability was determined by MTT assay. Incubation time was 
24 hours incubation of doxorubicin, then another 24 hours co-incubation of doxorubicin and 
tnashinone IIa. Data were expressed as means and s.e.m., n=6 for separate experiments, each 
with triplicate determinations. ### p<0.001, compare with control; SPSS, one way ANOVA. 
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3.5. Doxorubicin-induced nitric oxide production 
3.5.1. DAF-2 DA assay 
The standard concentration curve of DAF-2 DA was firstly established using a NO 
donor, spermine NONOate (0.01-20µM) (Figure 22). 
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Figure 22. Standard NO curve by DAF-2 DA assay using different concentrations spermine 
NONOate (0.01-20µM) as a NO donor. The half life of spermine NONOate in 0.1M, 
phosphate buffer (PH 7.4) at 37°C is t1/2 (39min.). Data were expressed as means and s.e.m., 
n=3 for repeated experiment each with triplicate determinations; SPSS, one way ANOVA. 
 
Incubation of H9C2 cells with doxorubicin (1µM) for 24 hours did not cause significant 
changes of NO fluorescence intensity when the data were expressed as the absolute value 
(Figure 23). However, when the NO fluorescence intensity was expressed as per cell 
population (Fluorescence intensity/1*10^4cells), doxorubicin significantly increased NO 
fluorescence intensity which was inhibited by the NOS inhibitor L-NAME (100µM) (Figure 
23). In addition, doxorubicin (1µM) itself had a fluorescence (excitation: 460-490nm, 
emission: 510nm-560nm) (Figure 25 taken by a Nikon camera under the microscopy). It also 
had an absorbance at 340nm-640nm, with a peak value at 485nm (Figure 24).  
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Figure 23. Changes of NO fluorescence intensity by doxorubicin (1µM) and NOS Inhibitor 
L-NAME (100µM) in H9C2 cells measured by DAF-2 DA (10µM) assay. Incubation time: 24 
hours. Data were expressed as means and s.e.m., n=3-4 for repeated experiment each with 
triplicate determinations. Left panel shows the absolute value of NO fluorescence intensity, 
right panel shows the NO fluorescence intensity per cell population; SPSS, one way ANOVA.  
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Figure 24. Doxorubicin-induced (1µM) fluorescence absorbance at 340nm-640nm. 
 61 
 
Figure 25. Fluorescence of doxorubicin. Left panel was under the normal light; right panel 
was fluorescence of doxorubicin, Excitation: 460-490nm, emission: 510nm-560nm. 
 
3.5.2. Nitrite assay  
Doxorubicin (1µM) caused a significant increase in NO concentration in cell media, 
measured by the end product of NO. The effect of doxorubicin was significantly inhibited by 
the selective iNOS inhibitor L-NIL (300µM) (Figure 26). The level of NO concentration in 
control cell media was 8nM, compared to that in doxorubicin treated cells (11nM) and 
doxorubicin plus L-NIL groups (4nM) (p<0.001, SPSS, one way ANOVA).  
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Figure 26. Changes of NO concentration in cell media by 1µM doxorubicin and the effect of 
NOS inhibitor L-NIL (300µM) in H9C2 cells measured by nitrite assay. Incubation time: 24 
hours. Data were expressed as means and s.e.m., n=3-6 for repeated experiment each with 
triplicate determinations. ## p<0.01, ### p<0.001, compare with control; *** p<0.001, 
compare with doxorubicin; SPSS, one way ANOVA. 
 
Similarly the NO production induced by doxorubicin (1µM) was significantly inhibited 
by the Cell permeable SOD mimetic MnTBAP 30µM (Figure 27), it showed peroxynitrite had 
been resumed to normal level 8nM.  
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Figure 27. Changes of NO concentration in cell media by doxorubicin (1µM) and the Effect 
of SOD MnTBAP (30µM) in H9C2 Cells Measured by Nitrite Assay. Incubation time: 24 
hours. Data were expressed as means and s.e.m., n=3-6 for repeated experiment each with 
triplicate determinations. ### p<0.001, compare with control; *** p<0.001, compare with 
doxorubicin; SPSS, one way ANOVA. 
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In separate experiments, the NO production induced by doxorubicin (1µM) was also 
significantly inhibited by tanshinone IIa (Figure 28).  
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Figure 28. Changes of NO concentration in cell media by doxorubicin (1µM) and the effect 
of tanshinone IIa (0.1-10µM) in H9C2 cells measured by nitrite Assay. Incubation time: 24 
hours. Data were expressed as means and s.e.m., n=3 for repeated experiment each with 
triplicate determinations. ## p<0.01, compare with control; ** p<0.01, compare with 
doxorubicin; SPSS, one way ANOVA. 
 
3.6. Effects of Synthetic tanshinone IIa derivatives on doxorubicin-induced cell toxicity 
3.6.1. Effects of AFC compounds on cell viability 
Figure 29 shows the effects of eight synthetic derivatives (AFC1-8) on the cell viability 
in H9C2 cells. AFC1, AFC2, AFC3, AFC4, and AFC8 had no significant effects (p>0.05) on 
cell viability after 24 hours incubations. AFC5 slightly increased the cell viability (107%) 
only at a high concentration (30µM). AFC6 slightly inhibited the cell viability at all 
concentrations tested. AFC7 reduced the cell viability at 0.3µM, 3µM, and 10µM (p<0.05, 
one way ANOVA) (Figure 29). On the other hand, 48 hours incubation of all AFC 
compounds at 3µM resulted slight increase cell viability by AFC1, AFC2, and AFC4 (112%, 
115% and 109%), respectively. While other compounds (AFC3, AFC5, AFC6, AFC7, and 
AFC8) had no significant effects (Figure 30). 
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3.6.2. Effects of AFC compounds against doxorubicin-induced cell death 
Figure 31 shows the effects of concurrent incubation (24 hours) of doxorubicin with 
synthetic derivatives (AFC1-8, 0.1-30µM) on the cell viability in H9C2 cells. AFC1 (0.3µM, 
1µM, 3µM, and 10µM) and AFC2 (1µM) significantly reduced the doxorubicin-induced cell 
death after 24 hours incubation. AFC3, AFC4 (exclude 0.1µM), AFC5, AFC6, AFC7, and 
AFC8 had no significant (p>0.05) effects against doxorubicin-induced cell death in H9C2 
cells. 
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Figure 29. Effects of AFC compounds (0.1-30µM) on cell viability on H9C2 cells. Cell 
viability was determined by MTT assay. Incubation time 24 hours. Data were expressed as 
means and s.e.m., n=3 for repeated experiment each with triplicate determinations. * p<0.05, 
** p<0.01, compare with control; SPSS, one way ANOVA.  
 
 66 
AFC1-8
0
20
40
60
80
100
120
CON 1 2 3 4 5 6 7 8
C
e
ll
 V
ia
b
il
it
y
(%
)
# #
##
 
Figure 30. Effects of AFC compounds (3µM) on cell viability on H9C2 cells. Cell viability 
was determined by MTT assay. Incubation time 24 hours. Data were expressed as means and 
s.e.m., n=3 for repeated experiment each with triplicate determinations. # p<0.05, compare 
with control; one way ANOVA. 
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Figure 31. Effects of AFC compounds (0.1-30µM) on 1µM doxorubicin-induced cell death in 
H9C2 cells. Cell viability was determined by MTT assay. Incubation time 24 hours. Data 
were expressed as means and s.e.m., n=3-12 for separate experiments each with quadruplicate 
determinations. ### p<0.001, compare with control; * p<0.05, ** p<0.01 compare with 
doxorubicin; one way ANOVA. 
 
In some experiments, cells were pre-incubated with AFC compounds (3µM) for 24 
hours first, and then subjected to doxorubicin (1µM) for another 24 hours. In these 
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experiments, AFC5, AFC6, and AFC7 (3µM) significantly reduced the doxorubicin-induced 
cell death (Figure 32)  
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Figure 32. Effects of AFC compounds (3µM, 24 hours pre-incubation) on 1µM doxorubicin-
induced cell death in H9C2 cells. Cell viability was determined by MTT assay. Incubation 
time 24 hours for doxorubicin. Data were expressed as means and s.e.m., n=3-6 for repeated 
experiment each with triplicate determinations. ## p<0.01, compare with control; * p<0.05 
compare with doxorubicin; SPSS one way ANOVA. 
 
In separate experiments, cells were pre-incubated with doxorubicin 1µM for 24 hours 
first, and then subjected to AFC compound for another 24 hours. Under this condition, AFC1 
(3µM), AFC2 (1µM), and AFC3 (10µM) at the concentrations tested had no significant effect 
against doxorubicin induced cell death (Figure 33).  
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Figure 33. Effects of AFC compounds (24 hours after doxorubicin incubation) on 1µM 
doxorubicin-induced cell death in H9C2 cells. Cell viability was determined by MTT assay. 
n=6 for repeated experiment each with triplicate determinations. ## p<0.01, compared with 
control; ### p<0.001, compared with control; SPSS, one way ANOVA. 
 
3.6.3. Effects of AFC compounds on doxorubicin-induced NO production 
NO production induced by doxorubicin 1µM was significantly inhibited by AFC1 (1-
3µM). The NO level in the control group was 9.0nM, compared to 1µM doxorubicin group 
(11.8nM). Combination 1µM doxorubicin and 0.3µM AFC1 reduced NO level to 6.9nM. 
AFC at 10µM did not significantly affect the NO production. (Figure 34) 
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Figure 34. Effects of AFC1 on 1µM doxorubicin-induced NO production in cell media, 
measured by nitrite assay. Incubation time was 24 hours. n=3 for repeated experiment each 
with triplicate determinations. ## p<0.01, compare with control; * p<0.5, ** p<0.01, compare 
with doxorubicin; SPSS, one way ANOVA. 
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Similar results were obtained for AFC2. AFC2 (0.3 and 1µM) significantly inhibited 
doxorubicin-induced NO production, from 10.7nM to 7.9nM and 7.8nM by 0.3 and 1µM 
AFC2 respectively (p<0.01, one-way ANOVA) (Figure 35). 
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Figure 35. Effects of AFC2 on 1µM doxorubicin-induced NO production in cell media, 
measured by nitrite assay. Incubation time was 24 hours. Data were expressed as means and 
s.e.m., n=3 for repeated experiment each with triplicate determinations. ## p<0.01, compare 
with control; * p<0.5, ** p<0.01, compare with doxorubicin; one way ANOVA. 
 
3.7. Discussion 
An important approach for searching novel agents for preventing or limiting 
doxorubicin-induced cardiotoxicity is to study the actions of effective natural compounds and 
to identity the mechanisms involved in their actions and then to develop more effective 
derivatives (see Chapter 1). The work described in this Chapter was designed to investigate 
the link between endogenous NO production and the cardioprotective actions of tanshinone 
IIa and derivates on doxorubicin-induced toxicity and in cultured cardiac cells. The overall 
findings that tanshinone IIa and some of its derivatives inhibited both doxorubicin-induced 
cell death and NO production indicate a strong association between these effects. In addition, 
the effects of iNOS inhibitor L-NIL and cell-permeable SOD mimetic MnTBAP on 
doxorubicin-induced cell death have been confirmed in the present study, which are also 
associated with their inhibitory actions on NO productions. These results are in line with the 
recent finding that NO pathway, in particular peroxynitrite, a product of NO and superoxide, 
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is a major trigger of doxorubicin induced cell death both in vitro and in vivo (Mukhopadhyay 
et al., 2009). Importantly, the association/link between the effects of tanshinone IIa on 
doxorubicin-induced cardiotoxicity and endogenous NO pathway has not been reported 
previously, thus, the new finding obtained in the present study is new and important for 
understanding the mechanism of actions of cardioprotective actions of tanshinone IIa and 
related compounds and forms a basis for further study for developing agents for preventing or 
limiting doxorubicin-induced cardiotoxicity. Moreover, 12-hour point is higher than 6-hour 
point is not clear. It may be due to the growth feature of H9C2 cells under specific 
experimental conditions. Further experiments are necessary to confirm this result and 
investigate possible mechanisms involved. 
Doxorubicin was previously shown to cause increase in cellular generation of oxidative 
radicals such as superoxide (Gervasi et al., 1990). Recently it has been reported to active 
iNOS and cause significant NO production in cardiac cells (Mukhopadhyay et al., 2009). 
Such due effects of doxorubicin result in the formation of harmful peroxynitrite, which in turn 
causes cell damages and cell death (Todorova et al., 2010). In the present study, the inhibition 
of iNOS-mediated NO production and cell toxicity by the selective iNOS inhibitor L-NIL 
supports a role of NO s in doxorubicin-induced cardiotoxicity (Mukhopadhyay et al., 2009). 
However, at the concentrations tested L-NIL did not show a concentration-dependent effect. 
The reason for that is not clear. One possible explanation is that it may reach a maximal effect 
at 100µM. NIL In the present study none of the concentrations of L-NIL tested affected the 
cell viability by its own.  
H9C2 cells have been studied using DAF-2 to measure endogenous NO production 
(Dedkova et al., 2004). In the present study, 4,5-diaminofluorescein-2 diacetate (DAF-2 DA), 
was used as a cell permeable non-fluorescent reagent. This compound was subsequently 
hydrolysed by cytosolic esterases to release DAF-2 which then reacts with cellular NO (in the 
presence of O2) to form a fluorescent triazole derivative, DAF-2 T. 1µM Doxorubicin-induced 
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a significant increase in fluorescence intensity measured at 510nm. Since this fluorescence 
intensity was inhibited by the NOS inhibitor L-NAME it suggests that doxorubicin induced 
NOS-mediated NO production in H9C2 cells. However, it should be pointed out that the way 
to analyse/express the data is important, since if using the absolute fluorescence intensity, 
there were no differences between doxorubicin and control groups. This can be explained that 
doxorubicin also causes the cell death, and the NO signal is only derived from the viable 
living cells, so the data should be expressed fluorescence per cells but the absolute value, 
otherwise, the control group would have more viable cells than the doxorubicin group thus 
mask the effect of doxorubicin. In addition, doxorubicin has been shown with own 
fluorescence, with an excitation wavelength at around 485nm and emission fluorescence 
peaks of doxorubicin and its metabolites at 550nM and 585nM (Yuh et al., 2005).This is same 
to DAF-2 T (excitation wavelength at 485nm and emission at 510nm). Thus the close 
wavelength emission of doxorubicin and DAF-2 T indicates interference may occur with 
these compounds. Thus indicates that DAF-2 DA may not be suitable agent to study the 
production of NO generation induced by doxorubicin. Tanshinone IIa has a stable baseline 
fluorescence around 535nm; the fluorescent intensity of cells after tanshinone IIa addition 
have to normalized the baseline which pretreated tanshinone IIa as control (Dai et al., 2011). 
So, similarly DAF-2 DA may not be suitable to study the effect of tanshinone IIa on NO 
production as it also has similar fluorescence activity. Thus the subsequent experiments were 
conducted using nitrite assay to measure the end product of ON in cell medium, as an indirect 
measure of cellular NO production. Similarly doxorubicin-induced a significant increase in 
NO level, which was inhibited by the iNOS inhibitor L-NIL, indicting it is derived from iNOS. 
The effects of SOD mimetic and peroxynitrite scavenger MnTBAP on doxorubicin 
toxicity support the role of superoxide-related mechanism (peroxynitrite) in doxorubicin-
induced cell toxicity. It may be possible that doxorubicin-induced NO production may be 
transformed quickly to peroxynitrite which is sensitive to MnTBAP (Dedkova and Blatter, 
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2009), since MnTBAP is not a NO scavenger and did not affect iNOS-mediated NO 
production by LPS (Zingarelli et al., 1997). On the other hand, a superoxide-mediated NO 
production has been reported in cultured glioma cells and PC12 cells (Manning et al., 2001; 
Yuyama et al., 2003). Thus it is not clear if a similar mechanism is also involved in 
doxorubicin-induced NO production in H9C2 cells. Further study on the effects of MnTBAP 
on ROS production and relationship with NO pathway is necessary before a conclusion can be 
drawn.  
Tanshinone IIa has been reported with inhibitory actions on ROS generation and 
apoptosis signalling pathways (Hong et al., 2010). It has also been shown to inhibit iNOS 
induction and NO production in other cells such as RAW 264.7 cells (Jang et al., 2003). 
Tanshinone IIa has also been shown to activate eNOS to exert a cardioprotective effect (Li et 
al., 2008; Pan et al., 2011). In the present study, tanshinone IIa protected doxorubicin-induced 
cell death, which is associated with its inhibition of iNOS-mediated NO production in H9C2 
cells.  
The effect of tanshinone IIa is concentration dependent, as at high concentrations (e.g. 
10µM) it was ineffective. This is most likely due to the fact tanshinone IIa is also cell toxic at 
high concentrations (Yang et al., 2005). It inhibited tumour growth (Lee et al., 2010). Thus 
the benefit effect of tanshinone IIa in precenting or reducing doxorubicin-induced toxicity is 
limited to the low concentrations of tanshinone IIa. This finding may have implication for 
developing tanshinone IIa as therapeutic agent. On the other hand, tanshinone IIa has been 
used clinically for treating certain cardiovascular conditions (Gao et al., 2011). However, it 
has a low bioavailability (Hu et al., 2010), thus there is a need to develop more effective and 
potent tanshinone IIa related compounds for its therapeutic applications. 
Among the synthetic compounds tested, AFC1 was most potent against doxorubicin-
induce cardiotoxicity in H9C2 cells, the rank order of potency is 
(AFC1 >AFC2>AFC3>AFC5>AFC6>AFC7>AFC4). Preliminary tests on AFC1 and AFC2 
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indicate that a similar inhibitory action of AFC compounds on NO production, indicating it 
has similar actions to tanshinone IIa. Thus, the protective effect of AFC compounds on 
doxorubicin-induced cell toxicity is associated with their actions on NO production. 
The structure difference between these AFC compounds is the AFC1 and AFC 2 
containing –NO2 group while other compounds not. Thus the –NO2 group seems important 
for the actions of AFC compounds against doxorubicin-induced cardiotoxicity. Further study 
is necessary to study the detailed structure-response relationship of AFC1 and related 
compounds for obtaining a more potent compound. The observation that relative higher 
concentration of AFC1 (3µM) increased the cell viability indicates that this compound may 
promote the cell growth at higher concentrations. 
The 24 hours combination treatment showed AFC2 against doxorubicin- induce toxicity 
is lower than AFC1. However, when only using AFC2 in myocardial cells its prevention is 
stronger than AFC1. The antioxidant activity was lower than AFC1. When only using AFC4 
treat cells 48 hours showed it has benefit for heart cells. But when AFC4 combines with 
doxorubicin, it points out low concentration less than 0.3µM maybe increase doxorubicin 
toxicity. AFC5, AFC6, and AFC7 maybe have a protect activity if before using doxorubicin. 
If the myocardial cells have been damaged, using AFC1, AFC2, and AFC3 could not be 
change anything. 
In conclusion, the finding from studies described in this chapter indicates a close 
association of between endogenous NO pathway with the protective actions of tanshinone IIa 
and related compounds on doxorubicin-induced cardiotoxicity. Further studies are necessary 
for looking into mechanisms of actions of these compounds and structure-response 
relationship of AFC1 and related compounds for searching more effective compounds for 
clinical applications. 
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4.1. Outcome of the project  
The main objective of this thesis was to study the actions of natural products on 
doxorubicin-induced cardiotoxicity. To achieve this objective, two approaches have been 
undertaken, firstly, conducting a general literature review for most updated information on the 
effects of various natural products, including plant extracts, formulations and active purified 
compounds and their derivatives on doxorubicin-induced cardiotoxicity, and secondly, 
conducting a specific experimental study in vitro to investigate the links between endogenous 
NO pathway and the cardioprotective actions of tanshinone IIa, the active compound of 
Danshen and its derivatives on doxorubicin-induced cell death in H9C2 cells in vitro. The 
main outcomes of the project is experimental findings which not only confirm the reported 
actions of tanshinone IIa on doxorubicin-induced toxicity in cardiac cells, but also 
demonstrated for the first time that the actions of tanshinone IIa and some of its derivatives 
were associated with an inhibitory on endogenous NO production which was activated by 
doxorubicin. Such findings are important for further studies on mechanism of actions of 
tanshinone IIa and its derivative for developing novel agents for protecting and limiting 
doxorubicin-induced cardiotoxicity. Given tanshinone IIa has already been used clinically for 
treating cardiovascular diseases and cancers, there is a certainly potential for using tanshinone 
IIa and its derivatives for treating doxorubicin-induced cardiotoxicity. The findings of this 
project contribute to new knowledge of our current understanding of actions of natural 
products on doxorubicin-induced cardiotoxicity. 
The identification of link between the actions of tanshinone IIa and derivatives NO is 
important as it may relate to the mechanism of actions of tanshinones and related compounds 
given that it has been recently shown that NO plays an important role in doxorubicin-induced 
cardiotoxicity. However, the possibility it is not clear whether tanshinone IIa acts by 
inhibiting NOS directly or through inhibition of ROS production which results in decrease in 
the formation of harmful peroxynitrite. In addition, the possibility cannot be totally excluded 
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that such actions of tanshinone IIa may be derived from an unknown action of these 
compounds on other signalling pathways related to doxorubicin cardiotoxicity. As far as 
synthetic compounds are concerned, their actions are similar to tanshinone IIa, although some 
are more potent than others. Due to the limit of time, the present study was not be able to 
analyse further the mechanisms of actions of these compounds and their structure-response 
relationships. Nevertheless the outcome of this project paved a foundation for further studies 
of actions of these compounds on cardiac damages induced doxorubicin and other 
pathological factors or agents. The findings also support to validate studies on other related 
compounds or herbal medicines on doxorubicin-induced cardiotoxicity. The goal is to identify 
a lead molecule which offers a better and more potent action then tanshinone IIa and other 
compounds for further clinical studies. 
Certain natural products/compounds possess both antioxidant and anticancer actions 
(see Chapter 2), which makes them potentially useful as a complementary therapy for treating 
doxorubicin-induced cardiotoxicity. Unlike western drugs, natural products generally have a 
low toxicity thus with a good safty profile, which would be an important consideration in 
further development of new therpies for anti-doxorubicin induced cardiotocxicity. However, 
the selection of natural products, in paticular the relevant dosage and bioavialability in vivo 
are important. Certain products may have excellent activity in vitro but failed to demonstrate 
its effecacy in vivo or in clinical trials. There are various factors on this including species 
differences or poor bioavailability of these compounds in vivo. Curremntly there is still 
limited qulity clinical studies on the efficacy and safety of natural products on doxorubicin-
induced toxicty. In the present study, tanshinone IIa at high concentrations induced the cell 
toxicity by which may be related to its anticancer actions (Lee et al., 2010). Thus, it is 
important to study further both anticancer and anticardiotoxicity actions of tanshinones IIa to 
establish a proper concentration (dosage) of this compound in vivo in particualr in human.  
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4.2. Limitations of this thesis 
There are several limitations of this study. Firstly, due to the limit of time, the effects of 
tanshinone IIa and other derivatives on doxorubicin-induced toxicity were only evaluated 
using cell viability assay. Further measurements of markers known involved in doxorubicin –
induced cell damages in H9C2cell such as LDH and/or apoptosis proteins would generate 
more information on doxorubicin-induced cardiotoxicity and also additional mechanisms of 
actions of tanshinone IIa derivatives. Secondly, there has been a challenge in using DAF-2 
DA to measure production of NO in H9C2 cells. Although there is an advantage in using 
DAF-2 DA as it can monitor the production of intracellular NO in real time, the interference 
of doxorubicin on cell growth and the absorbance by doxorubicin itself masked the real 
cellular measurement values. Thus, it may limit the use of this dye in the study of 
doxorubicin-induced NO production. In fact there is still no published report in the literature 
on using DAF-2 DA in monitoring NO production induced by doxorubicin. Nevertheless it 
has been demonstrated in this study that DAF-2 DA can be used for measuring the NO 
generation in doxorubicin-induced cells, although the data analysis is important (see 
discussion in Chapter 3). The results of NO sensor study also support the involvement of NO 
in the actions of tanshinone IIa and derivatives. Thirdly, the evidence of involvement of NO 
pathway in actions of tanshinone IIa and derivative is limited to NO generation. It is not clear 
if the results are due to the changes of NOS or the substrate or co-factors of NOS. Finally, the 
present study by nature is in vitro, thus the findings should be explained carefully and be 
further confirmed by studies in vivo.   
 
4.3. Future directions  
 A number of future studies can be undertaken to enhance our understanding the 
actions and mechanisms of tanshinone IIa and derivatives on doxorubicin-induced 
cardiotoxicity. Firstly, there is a need to study the further mechanism of actions of tanshinone 
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IIa and derivatives on NO pathway, including the expressions of NOS isoforms and/or NOS 
activities, such as using molecular biology methods and 3H-arginine methods (Liu et al., 
2011). The activities of these compounds on the peroxynitrite-induced cellular changes should 
also be investigated, including testing if these compounds may directly scavenge peroxynitrite 
and their actions on peroxynitrite-induced protein nitration and apoptosis signalling pathways. 
This is important given that peroxynitrite can trigger cell death and induce both cellular 
apoptosis and necrosis, targeting mitochondrial signalling pathways which are critical in cell 
survival under various stress conditions (Szabo et al., 2007). Secondly, there is a need to 
study the actions of these compounds especially new synthetic compounds on the generation 
of ROS and activities of related enzymes such as NADPH-oxidase (NOX), catalase, SOD, 
and GSH-Px activities etc. Thirdly there is a need to study the structure-response relationship 
of synthetic compounds against NO production and doxorubicin-induced cardiotoxicity. 
Fourthly, it will be important to investigate the influences of these compounds on the anti-
tumour actions of doxorubicin to see whether the active compounds affect the therapeutic 
actions of doxorubicin. Finally, it is critical to investigate the effects of these compounds on 
doxorubicin-induced cardiotoxicity in vivo e.g. using established methods (Zhou et al., 1999). 
These have been reports on clinical applications of using tanshinone IIa in treating certain 
cancers (Yuan et al., 2003), tanshinone IIa had been used on cancer effort syndrome treatment 
(Ge et al., 2009), thus further analysis of clinical data and/or conducting a well-designed 
clinical trial will ultimately establish the value of tanshinone IIa and related compounds in 
preventing or limiting doxorubicin-induced cardiotoxicity. It is believed that further research 
in this area will lead to the development if a novel complementary therapy for enhancing the 
clinical applications of doxorubicin and related drugs, which will benefit the mankind.  
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Appendix 
Abbreviations 
ABVD Doxorubicin, bleomycin, vinblastine, dacarbazine 
AST Aspartate aminotransferase 
ATCC American Type Culture Collection 
ATM kinase Ataxia telangiectasia mutated kinase 
Bax Bcl-2–associated X protein 
Bcl-2 B-cell lymphoma 2 
Bcl-xl B-cell lymphoma-extra lone 
Bcl-xs B-cell lymphoma-extra short 
BUN Blood urea nitrogen 
Ca2+ Calcium 
CB1 receptor Cannabinoid 1 receptor type 
CCR Creatinine clearance rate 
CK Creatine kinase 
CON Control 
CoQ Coenzyme Q, ubiquinone 
CPK Creatine phosphokinase 
CPK-MB Creatine phosphokinase-MB 
CHOP Cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone or 
prednisolone 
CTGFp Connective tissue growth factor protein 
DAF-2 4,5-diaminofluorescein 
DAF-2 DA DAF-2 diacetate 
DAF-2 T Triazolofluorescein 
DMEM Dulbecco's modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOX Doxorubicin, Adriamycin 
DPBS Dulbecco’s Phosphate Buffered Saline 
DVd Dexamethasone and liposomal doxorubicin 
EC50 Half maximal effective concentration 
ECG Electrocardiography 
ECG Epicatechin gallate 
EDTA Ethylenediaminetetraacetic acid 
EGC Epigallocatechin 
EGCG Epigallocatechin gallate 
ERKs Extracellular signal-regulated kinases 
FAAH Fatty acid amide hydrolase 
Fe2+ Ferrous 
Fe3+ ferric 
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Gem Gemcitabine 
GST Glutathione-S transferase 
GSH-Px glutathione peroxidase 
H2O2 hydrogen peroxide 
HCL Hydrochloric acid 
IC50 Half maximal inhibitory concentration 
ICRF-159 Razoxane 
ICRF-187 Dexrazoxane, Zinecard 
iNOS Inducible nitric oxide synthase 
JNKs c-Jun N-terminal kinases 
LDH Lactate dehydrogenase 
L-NAME Nω-Nitro-L-arginine methyl ester hydrochloride 
L-NIL L-N6-(1-Iminoethyl)lysine hydrochloride 
MACOP-B Methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin and 
prednisone 
MAPKs Mitogen-activated protein kinases 
MDA Malondialdehyde 
MMP Matrix metalloproteinase 
MnTBAP Mn(III)tetrakis(4-benzoic acid)porphyrin chloride 
MPTP Mitochondrial permeability transition pore 
mRNA Messenger ribonucleic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NFкB Nuclear factor кB 
NO Nitric oxide 
NOS Nitric oxide synthase 
NOS I (type 
1 NOS, 
nNOS) 
Neuronal nitric oxide synthase 
NOS II (type 
2 NOS, 
iNOS) 
Inducible nitric oxide synthase 
NOS II (type 
3 NOS, 
eNOS) 
Endothelial nitric oxide synthase 
O2 Oxygen 
O2
- Superoxide onion 
OH- hydroxyl radical 
ONOO- peroxynitrite 
p probability 
p53 protein 53  
PDGF-BB platelet-derived growth factor-BB 
P-gp P-glycoprotein 
PLD Polyethylene glycol liposomal doxorubicin 
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PPAR-α peroxisome proliferator-activated receptor-α 
ROS reactive oxygen species 
Scr proteinuria serum creatinine 
SERCA2a Sarco(endo)plasmic reticulum Ca2+ ATPases 
SMAC/DIA
BLO 
Second Mitochondria-derived Activator of Caspases/Direct IAP Binding 
Protein with Low PI 
SOD Superoxide dismutase 
Spermine 
NONOate 
(Z)-1-[N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]-
amino]diazen-1-ium-1,2-diolate 
TIIa Tanshinone IIa 
TGF-β Protein transforming growth factor-β 
TGF-β 
receptor I or 
II 
TbetaR I or II 
TNF-α Tumour necrosis factor-α 
TOP2 topoisomerase II  
VAD vincristine, dexamethasone and doxorubicin 
VCAP vindesine, doxorubicin, cyclophosphamide and prednisone 
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